Intestinal Research

Original Articles

Prevalence and outcome of sarcopenia in patients with inflammatory bowel disease: a follow-up study: Vikram Dharap, Devendra Desai, Philip Abraham, Tarun Gupta, Pavan Dhoble, Nirad Mehta, Jagdish Modhe; Received June 24, 2024 Accepted October 19, 2024 Published online January 23, 2025; DOI: https://doi.org/10.5217/ir.2024.00096 [Epub ahead of print]

Abstract PDF PubReader ePub: Background/Aims
Sarcopenia is implicated in inflammatory bowel disease (IBD) complications and surgical outcomes. This study aimed to investigate the prevalence and follow-up of sarcopenia in patients with IBD.
Methods
Consecutive consenting patients with IBD aged > 18 years were included. Patients with associated sarcopenic diseases were excluded. All had measurements of anthropometry, body mass index (BMI), mid-arm muscle circumference, muscle strength, physical performance, and muscle mass (on computed tomography scan). They were followed up for up to 12 months, and incidence of flares, fractures, and surgery was noted.
Results
Of 157 patients screened, 35 refused participation; 5 with associated sarcopenic diseases were excluded. Of 117 patients (median age, 41 years; interquartile range, 18–81 years; 65 men), 73 had ulcerative colitis, 42 Crohn’s disease, and 2 IBD-unclassified. Forty (34.2%) had probable sarcopenia; 47 (40.2%) had sarcopenia (29 ulcerative colitis and 18 Crohn’s disease) including 10 (8.5%) with severe sarcopenia. Ten (21.3%) were in disease remission. Of factors associated with sarcopenia in univariate analysis, only BMI was significant in multivariate analysis. Ninety-nine patients followed up for a median of 7 months (interquartile range, 2–12 months). Freedom from flares was 5.3% in patients with sarcopenia and 46.1% in those without (P= 0.004). Three patients (1 with sarcopenia, 2 without) required surgery.
Conclusions
Sarcopenia was present in 40% of patients with IBD; one-fifth of these had severe sarcopenia. One-fifth were in remission. Low BMI correlated with sarcopenia. More patients with sarcopenia had disease flare. Screening for sarcopenia should be considered in patients with IBD.

900 View
133 Download

Clinical characteristics and long-term disease course in patients with Crohn’s disease as diagnosed by video capsule endoscopy: a multicenter retrospective matched case-control study: June Hwa Bae, Su Hyun Park, Jung-Bin Park, Ji Eun Baek, Seung Wook Hong, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Kyeong Ok Kim, Byung Ik Jang, Mi Rae Lee, Eun Soo Kim, Sang Hyoung Park; Received April 18, 2024 Accepted July 15, 2024 Published online August 29, 2024; DOI: https://doi.org/10.5217/ir.2024.00056 [Epub ahead of print]

Abstract PDF PubReader ePub: Background/Aims
Video capsule endoscopy is rarely used to diagnose Crohn’s disease in patients with negative ileocolonoscopy or cross-sectional image findings. We evaluated clinical characteristics and long-term outcomes of these rare cases.
Methods
This multicenter study included patients with Crohn’s disease from 3 tertiary hospitals from January 2007 to October 2022. Patients with normal findings on ileocolonoscopy and computed tomography (CT)/magnetic resonance (MR) enterography but had ulcerations at the small bowel detected by video capsule endoscopy were included. The controls were patients with abnormal findings on endoscopy or CT/MR enterography. Controls were case-matched in a ratio of 3:1 for sex, calendar year of diagnosis, and age at diagnosis.
Results
Among 3,752 patients, 24 (0.6%) were diagnosed with Crohn’s disease using video capsule endoscopy findings. The disease location (P< 0.001) and behavior at diagnosis (P= 0.013) of the cases significantly differed from that of controls. The perianal fistula modifier (25.0% vs. 33.3%, P= 0.446) did not differ significantly between the 2 groups. Initial disease activity and C-reactive protein and fecal calprotectin levels were significantly lower in cases versus controls. The median Lewis score was 838 (interquartile range, 393–1,803). Over 10 years of follow-up, the cases showed significantly lower cumulative risk of complicated behavior, biologics use, Crohn’s disease-related hospitalization, and surgeries (log-rank test P< 0.05).
Conclusions
Patients with Crohn’s disease whose lesions were observed only by video capsule endoscopy were rare, and exhibit different clinical characteristics and a more favorable long-term disease course compared to those who were conventionally diagnosed.

1,792 View
145 Download

IBD

Changes in the clinical course and prognosis of ulcerative colitis in Chinese populations: a retrospective cohort study: Xinyu Liu, Qingfan Yang, Na Diao, Jian Tang, Zicheng Huang, Xiang Gao, Kang Chao; Intest Res 2024;22(3):357-368. Published online May 7, 2024; DOI: https://doi.org/10.5217/ir.2023.00106

Abstract PDF Supplementary Material PubReader ePub: Background/Aims
Data on the natural course of Chinese patients with ulcerative colitis (UC) was lacking. This study aimed to evaluate the natural history and prognosis of patients with UC in the past 15 years in China.
Methods
This cohort study included patients with UC in a tertiary hospital in southern China from 2007 to 2021 (cohort I: 2007–2011, cohort II: 2012–2016, cohort III: 2017–2021). Patients’ clinical characteristics and natural history were analyzed retrospectively.
Results
Of 1,139 included patients, 683 patients presented with proctitis or left-sided colitis at diagnosis and 38.5% of them (263/683) developed proximal disease extension. Fifty-eight percent of patients experienced relapse, chronic continuous and intermittent active course. Five patients (0.4%) developed colorectal tumors/dysplasia. The overall surgery rate was 8.6%, and the rates were 14.2%, 7.8%, and 8.0% in the 3 cohorts, respectively (P= 0.059). Average time from diagnosis to surgery decreased from cohorts I to III (144 months vs. 36 months, P< 0.001), so did the use of glucocorticoids (58.2% vs. 43.5%, P< 0.001) and immunosuppressants (14.1% vs. 13.4%, P= 0.016), and days of hospitalization (13 days vs. 9 days, P< 0.001). Biologics were used more frequently during the first year (0.8%, 2.1%, and 13.7% for cohorts I to III, respectively; P< 0.001). The rate of mucosal healing increased over time.
Conclusions
In Chinese UC patients, one-third of patients experienced proximal disease extension. The rates of malignancy and mortality were low. More biologics were used, while use of immunosuppressants and glucocorticoids were reduced over time. Early biologics use seemed to promote mucosal healing, but the rate of colectomy has not dramatically decreased.

2,623 View
177 Download
1 Web of Science

Review

Colorectal neoplasia

Pathogenesis and biomarkers of colorectal cancer by epigenetic alteration: Chang Kyo Oh, Young-Seok Cho; Intest Res 2024;22(2):131-151. Published online February 1, 2024; DOI: https://doi.org/10.5217/ir.2023.00115

Abstract PDF PubReader ePub

Colorectal cancer (CRC) ranks third in cancer incidence and stands as the second leading cause of cancer-related deaths globally. CRC tumorigenesis results from a cumulative set of genetic and epigenetic alterations, disrupting cancer-regulatory processes like cell proliferation, metabolism, angiogenesis, cell death, invasion, and metastasis. Key epigenetic modifications observed in cancers encompass abnormal DNA methylation, atypical histone modifications, and irregularities in noncoding RNAs, such as microRNAs and long noncoding RNAs. The advancement in genomic technologies has positioned these genetic and epigenetic shifts as potential clinical biomarkers for CRC patients. This review concisely covers the fundamental principles of CRC-associated epigenetic changes, and examines in detail their emerging role as biomarkers for early detection, prognosis, and treatment response prediction.

Citations

Citations to this article as recorded by

Influence of Lifestyles on Polyp Burden and Cancer Development in Hereditary Colorectal Cancer Syndromes
Hye Kyung Hyun, Ji Soo Park, Jihye Park, Soo Jung Park, Jae Jun Park, Jae Hee Cheon, Tae Il Kim
Journal of Gastroenterology and Hepatology.2025; 40(2): 433. CrossRef
The role of suppressor of cytokine signaling 3 in inflammatory bowel disease and its associated colorectal cancer
Pengfei Zhang, Bing Pei, Chengxue Yi, Francis Atim Akanyibah, Fei Mao
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.2025; 1871(2): 167578. CrossRef
Chronic Kidney Disease Increases Risk of Delayed Post‐Polypectomy Bleeding: A Large‐Scale Propensity Score‐Matched Analysis
Hye Kyung Hyun, Nak‐Hoon Son, So Hyeon Gwon, Hyun Chul Lim, Jihye Park, Soo Jung Park, Jae Jun Park, Jae Hee Cheon, Tae Il Kim, Tae‐Hyun Yoo, Shin‐Wook Kang, Hae‐Ryong Yun, Cheal Wung Huh
United European Gastroenterology Journal.2025;[Epub] CrossRef
An overview of potential of natural compounds to regulate epigenetic modifications in colorectal cancer: a recent update
Susmita Roy, Dikshita Deka, Suresh Babu Kondaveeti, Pavithra Ayyadurai, Sravani Siripragada, Neha Philip, Surajit Pathak, Asim K. Duttaroy, Antara Banerjee
Epigenetics.2025;[Epub] CrossRef
Minimum Platelet Count Threshold for Safe Colonoscopic Polypectomy: A Large-Scale Propensity Scored-Matched Analysis
Hye Kyung Hyun, Nak-Hoon Son, Cheal Wung Huh, Hyun Chul Lim, So Hyeon Gwon, Jihye Park, Soo Jung Park, Jae Jun Park, Jae Hee Cheon, Tae Il Kim
American Journal of Gastroenterology.2025;[Epub] CrossRef
miR-3065-5p and miR-26a-5p as Clinical Biomarkers in Colorectal Cancer: A Translational Study
Berenice Carbajal-López, Antonio Daniel Martínez-Gutierrez, Eduardo O. Madrigal-Santillán, Germán Calderillo-Ruiz, José Antonio Morales-González, Jossimar Coronel-Hernández, Joey Lockhart, Oliver Millan-Catalan, Monica G. Mendoza-Rodriguez, Leonardo S. Li
Cancers.2024; 16(21): 3649. CrossRef

5,358 View
221 Download
5 Web of Science
6 Crossref

Original Article

Microbiota

Compositional changes in fecal microbiota associated with clinical phenotypes and prognosis in Korean patients with inflammatory bowel disease: Seung Yong Shin, Young Kim, Won-Seok Kim, Jung Min Moon, Kang-Moon Lee, Sung-Ae Jung, Hyesook Park, Eun Young Huh, Byung Chang Kim, Soo Chan Lee, Chang Hwan Choi, on behalf of the IBD Research Group of the Korean Association for the Study of Intestinal Diseases; Intest Res 2023;21(1):148-160. Published online June 14, 2022; DOI: https://doi.org/10.5217/ir.2021.00168

Abstract PDF Supplementary Material PubReader ePub

Background/Aims
The fecal microbiota of Korean patients with inflammatory bowel disease (IBD) was investigated with respect to disease phenotypes and taxonomic biomarkers for diagnosis and prognosis of IBD.
Methods
Fecal samples from 70 ulcerative colitis (UC) patients, 39 Crohn’s disease (CD) patients, and 100 healthy control individuals (HC) were collected. The fecal samples were amplified via polymerase chain reaction and sequenced using Illumina MiSeq. The relationships between fecal bacteria and clinical phenotypes were analyzed using the EzBioCloud database and 16S microbiome pipeline.
Results
The alpha-diversity of fecal bacteria was significantly lower in UC and CD (P<0.05) compared to that in HC. Bacterial community compositions in UC and CD were significantly different from that of HC according to Bray-Curtis dissimilarities, and there was also a difference between community composition in UC and CD (P=0.01). In UC, alpha-diversity was further decreased when the disease was more severe and the extent of disease was greater, and community composition significantly differed depending on the extent of the disease. We identified 9 biomarkers of severity and 6 biomarkers of the extent of UC. We also identified 5 biomarkers of active disease and 3 biomarkers of ileocolonic involvement in CD. Lachnospiraceae and Ruminococcus gnavus were biomarkers for better prognosis in CD.
Conclusions
The fecal microbiota profiles of IBD patients were different from those of HC, and several bacterial taxa may be used as biomarkers to determine disease phenotypes and prognosis. These data may also help discover new therapeutic targets for IBD.

Citations

Citations to this article as recorded by

Gut bacteriome in inflammatory bowel disease: An update on recent advances
Aditya Bajaj, Manasvini Markandey, Saurabh Kedia, Vineet Ahuja
Indian Journal of Gastroenterology.2024; 43(1): 103. CrossRef
An Update on the Role and Potential Molecules in Relation to Ruminococcus gnavus in Inflammatory Bowel Disease, Obesity and Diabetes Mellitus
Jinni Hong, Tingting Fu, Weizhen Liu, Yu Du, Junmin Bu, Guojian Wei, Miao Yu, Yanshan Lin, Cunyun Min, Datao Lin
Diabetes, Metabolic Syndrome and Obesity.2024; Volume 17: 1235. CrossRef
Research advancements and perspectives of inflammatory bowel disease: A comprehensive review
Junyi Bai, Ying Wang, Fuhao Li, Yueyao Wu, Jun Chen, Meng Li, Xi Wang, Bin Lv
Science Progress.2024;[Epub] CrossRef
Integrated Analysis of Microbiome and Metabolome Reveals Disease-Specific Profiles in Inflammatory Bowel Diseases and Intestinal Behçet’s Disease
Yehyun Park, Jae Bum Ahn, Da Hye Kim, I Seul Park, Mijeong Son, Ji Hyung Kim, Hyun Woo Ma, Seung Won Kim, Jae Hee Cheon
International Journal of Molecular Sciences.2024; 25(12): 6697. CrossRef
Dynamic changes in the gut microbiota composition during adalimumab therapy in patients with ulcerative colitis: implications for treatment response prediction and therapeutic targets
Han Na Oh, Seung Yong Shin, Jong-Hwa Kim, Jihye Baek, Hyo Jong Kim, Kang-Moon Lee, Soo Jung Park, Seok-Young Kim, Hyung-Kyoon Choi, Wonyong Kim, Woo Jun Sul, Chang Hwan Choi
Gut Pathogens.2024;[Epub] CrossRef
Potential of Gut Microbe-Derived Extracellular Vesicles to Differentiate Inflammatory Bowel Disease Patients from Healthy Controls
Min Heo, Young Soo Park, Hyuk Yoon, Nam-Eun Kim, Kangjin Kim, Cheol Min Shin, Nayoung Kim, Dong Ho Lee
Gut and Liver.2023; 17(1): 108. CrossRef
Ruminococcus gnavus: friend or foe for human health
Emmanuelle H Crost, Erika Coletto, Andrew Bell, Nathalie Juge
FEMS Microbiology Reviews.2023;[Epub] CrossRef
The Relationship Between Rosacea and Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
Yu Kyung Jun, Da-Ae Yu, Yoo Min Han, Soo Ran Lee, Seong-Joon Koh, Hyunsun Park
Dermatology and Therapy.2023; 13(7): 1465. CrossRef
Risk of all-cause and cause-specific mortality associated with immune-mediated inflammatory diseases in Korea
Oh Chan Kwon, See Young Lee, Jaeyoung Chun, Kyungdo Han, Yuna Kim, Ryul Kim, Min-Chan Park, Jie-Hyun Kim, Young Hoon Youn, Hyojin Park
Frontiers in Medicine.2023;[Epub] CrossRef
Comments on Efficacy of a Synbiotic Containing Lactobacillus paracasei DKGF1 and Opuntia humifusa in Elderly Patients with Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial
Kwang Woo Kim
Gut and Liver.2023; 17(6): 954. CrossRef
Evaluation of Bacterial and Fungal Biomarkers for Differentiation and Prognosis of Patients with Inflammatory Bowel Disease
Hyuk Yoon, Sunghyouk Park, Yu Kyung Jun, Yonghoon Choi, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee
Microorganisms.2023; 11(12): 2882. CrossRef
A Machine Learning-Based Diagnostic Model for Crohn’s Disease and Ulcerative Colitis Utilizing Fecal Microbiome Analysis
Hyeonwoo Kim, Ji Eun Na, Sangsoo Kim, Tae-Oh Kim, Soo-Kyung Park, Chil-Woo Lee, Kyeong Ok Kim, Geom-Seog Seo, Min Suk Kim, Jae Myung Cha, Ja Seol Koo, Dong-Il Park
Microorganisms.2023; 12(1): 36. CrossRef

5,656 View
482 Download
12 Web of Science
12 Crossref

Review

IBD

Natural history of inflammatory bowel disease: a comparison between the East and the West: Eun Mi Song, Suk-Kyun Yang; Intest Res 2022;20(4):418-430. Published online December 2, 2021; DOI: https://doi.org/10.5217/ir.2021.00104

Abstract PDF PubReader ePub

Over the past decades, there has been a rapid increase in the incidence and prevalence of inflammatory bowel disease (IBD) in Asia. The natural history of IBD in Asian patients could be different from that in Western patients due to variations in disease phenotypes and genotypes as well as the healthcare environment between the 2 populations. To adequately cope with this disease, it is important to fully understand the potential differences in its natural history among different populations. In this review, we evaluated the differences in the clinical course of IBD between Asian and Western patients with regards to phenotypic progression, hospitalization, major surgery, risk of colorectal cancer, and mortality, mainly based on the results of population-based studies. The findings of our narrative review suggest that the clinical course of Asian patients with IBD, especially ulcerative colitis, is better than that of Western patients, as indicated by the lower rates of major surgery and hospitalization. In addition, similar to Western patients, the clinical course of Asian patients with IBD has been improving as evidenced by the decreasing rates of disease behavior progression (in Crohn’s disease), hospitalization, and major surgery.

Citations

Citations to this article as recorded by

Risk of avascular necrosis in patients with inflammatory bowel disease: Insights from a nationwide cohort study and the impact of corticosteroid use
Jung Min Moon, Kyoung-Eun Kwon, Ju Won Lee, Kyung Rok Minn, Kyuwon Kim, Jeongkuk Seo, Seung Yong Shin, Sun-Young Jung, Chang Hwan Choi
Digestive and Liver Disease.2025; 57(1): 176. CrossRef
Incidence of Venous Thromboembolism in Asian Patients With Inflammatory Bowel Disease: A Systematic Review and Meta‐Analysis
Joo Hye Song, Sung Ryul Shim, Dae Sung Kim, Hoon Sup Koo, Kyu Chan Huh
Journal of Gastroenterology and Hepatology.2025; 40(4): 774. CrossRef
Could histologic healing be a new treatment target in patients with ulcerative colitis?
Soyoung Kim, Sang Hyoung Park
The Korean Journal of Internal Medicine.2024; 39(1): 2. CrossRef
Inflammatory bowel disease evolution in the past two decades: a chronological multinational study
Pezhman Alavinejad, Seyed Jalal Hashemi, Nitin Behl, Ahmad Hormati, Abubakr Elbasuny, Naser Ebrahimi Daryani, Mehdi Pezeshgi Modarres, Masoud Arshadzadeh, Samira Panahande, Dao Viet Hang, Aya Mohammed Mahros, Abazar Parsi, Hazhir Javaherizadeh, Ata Rehman
eClinicalMedicine.2024; 70: 102542. CrossRef
Cytokine Profile in Predicting the Effectiveness of Advanced Therapy for Ulcerative Colitis: A Narrative Review
Hiroki Kurumi, Yoshihiro Yokoyama, Takehiro Hirano, Kotaro Akita, Yuki Hayashi, Tomoe Kazama, Hajime Isomoto, Hiroshi Nakase
Biomedicines.2024; 12(5): 952. CrossRef
Editorial: Another brick in the CDST wall: Authors' reply
Kyuwon Kim, Byong Duk Ye
Alimentary Pharmacology & Therapeutics.2024; 60(1): 87. CrossRef
Predictors of histologic remission in patients with biologic-naïve, moderate-to-severe ulcerative colitis treated with first-line biologic agents and small-molecule drugs: a single-center, retrospective cohort study
Kijae Jo, Kwang Woo Kim, Hyun Jung Lee, Jong Pil Im, Joo Sung Kim, Seong-Joon Koh
Intestinal Research.2024; 22(4): 453. CrossRef
Natural course of ulcerative colitis in China: Differences from the West?
Jian Wan, Jun Shen, Jie Zhong, Wensong Ge, Yinglei Miao, Xiaolan Zhang, Zhonghui Wen, Yufang Wang, Jie Liang, Kaichun Wu
United European Gastroenterology Journal.2024; 12(9): 1167. CrossRef
Prevalence and risk factors for gallstone and renal stone formation in patients with intestinal Behçet’s disease
Jaewon Song, Soo Jung Park, Jae Jun Park, Tae Il Kim, Jihye Park, Jae Hee Cheon
The Korean Journal of Internal Medicine.2024; 39(5): 770. CrossRef
Old and New Biologics and Small Molecules in Inflammatory Bowel Disease: Anti-Tumor Necrosis Factors
Sang Un Kim, Hyun Seok Lee
The Korean Journal of Gastroenterology.2024; 84(2): 35. CrossRef
Characteristics, clinical outcomes, and prognostic factors of colorectal cancer in patients with Crohn’s disease: American versus Korean tertiary referral center perspectives
Tanita Suttichaimongkol, Sung Wook Hwang, Nayantara Coelho-Prabhu, John B. Kisiel, Byong Duk Ye, Suk-Kyun Yang, Edward V. Loftus, Sang Hyoung Park
Therapeutic Advances in Gastroenterology.2024;[Epub] CrossRef
Primary surgery versus pharmacotherapy for newly diagnosed ileocecal Crohn’s disease: a hospital-based cohort study
Yehyun Park, Soo Jung Park, Tae Il Kim, Won Ho Kim, Jae Hee Cheon
The Korean Journal of Internal Medicine.2024; 39(5): 759. CrossRef
Anti-colitis efficacy of oxyresveratrol isolated from mulberry twig in dextran sulfate sodium-induced mouse colitis
Xuelei Cui, Jimin Lee, Sang-Won Choi, Eunjung Kim
Journal of Nutrition and Health.2024; 57(6): 567. CrossRef
Korean clinical practice guidelines on biologics for moderate to severe Crohn’s disease
Seong-Joon Koh, Sung Noh Hong, Soo-Kyung Park, Byong Duk Ye, Kyeong Ok Kim, Jeong Eun Shin, Yong Sik Yoon, Hong Sub Lee, Sung Hoon Jung, Miyoung Choi, Soo-Young Na, Chang Hwan Choi, Joo Sung Kim
Intestinal Research.2023; 21(1): 43. CrossRef
Long‐term clinical outcomes of intestinal Behçet's disease: A 30‐year cohort study at a tertiary hospital in South Korea
Jihye Park, Soo Jung Park, Jae Jun Park, Tae Il Kim, Jae Hee Cheon
Journal of Gastroenterology and Hepatology.2023; 38(3): 386. CrossRef
Past, present, and future of Intestinal Research
Jae Hee Cheon
Intestinal Research.2023; 21(1): 1. CrossRef
Association of Waist Circumference with the Risk of Inflammatory Bowel Disease: a Nationwide Cohort Study of 10 Million Individuals in Korea
Yeonjin Je, Kyungdo Han, Jaeyoung Chun, Yuna Kim, Jie-Hyun Kim, Young Hoon Youn, Hyojin Park, Jong Pil Im, Joo Sung Kim
Journal of Crohn's and Colitis.2023; 17(5): 681. CrossRef
Primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD): a condition exemplifying the crosstalk of the gut–liver axis
You Sun Kim, Edward H. Hurley, Yoojeong Park, Sungjin Ko
Experimental & Molecular Medicine.2023; 55(7): 1380. CrossRef
Treatment of inflammatory bowel disease–Asian perspectives: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting
Eun Mi Song, Soo-Young Na, Sung Noh Hong, Siew Chien Ng, Tadakazu Hisamatsu, Byong Duk Ye
Intestinal Research.2023; 21(3): 339. CrossRef
How have treatment patterns for patients with inflammatory bowel disease changed in Asian countries?
Jihye Park
Intestinal Research.2023; 21(3): 275. CrossRef
Treatment of primary sclerosing cholangitis combined with inflammatory bowel disease
You Sun Kim, Edward H. Hurley, Yoojeong Park, Sungjin Ko
Intestinal Research.2023; 21(4): 420. CrossRef
Golimumab for Ulcerative Colitis: One More Option to SAVE the Colon
Sang Hyoung Park
Crohn's & Colitis 360.2023;[Epub] CrossRef
Advancements in the Management of Moderate-to-Severe Ulcerative Colitis: A Revised 2023 Korean Treatment Guidelines
Soo-Young Na
The Korean Journal of Medicine.2023; 98(5): 223. CrossRef
Virofree Associates with the Modulation of Gut Microbiomes and Alleviation of DSS-Induced IBD Symptoms in Mice
Wei-Sheng Lin, Wan-Chen Cheng, Min-Hsiung Pan
ACS Omega.2023; 8(44): 41427. CrossRef
The Prevalence and Risk Factors of Clostridioides difficile Infection in Inflammatory Bowel Disease: 10-Year South Korean Experience Based on the National Database
Eun Mi Song, Arum Choi, Sukil Kim, Sung Hoon Jung
Journal of Korean Medical Science.2023;[Epub] CrossRef
Which biologic agents increase perioperative complications in patients with inflammatory bowel disease?
Jihye Park
Intestinal Research.2022; 20(1): 1. CrossRef
Is primary sclerosing cholangitis with inflammatory bowel disease different between patients in the East and West?
Yong Eun Park
Intestinal Research.2022; 20(2): 157. CrossRef
Bioactive Components and Potential Mechanism Prediction of Kui Jie Kang against Ulcerative Colitis via Systematic Pharmacology and UPLC-QE-MS Analysis
Jinbiao He, Chunping Wan, Xiaosi Li, Zishu Zhang, Yu Yang, Huaning Wang, Yan Qi, Ivan Luzardo-Ocampo
Evidence-Based Complementary and Alternative Medicine.2022; 2022: 1. CrossRef
Antiviral Prophylaxis Against Hepatitis B Virus in Patients Treated with Anti-Tumor Necrosis Factor α Agents for Inflammatory Bowel Disease
Eun Ae Kang, Jae Hee Cheon
Gut and Liver.2022; 16(4): 501. CrossRef
Personalized medicine in inflammatory bowel disease: Perspectives on Asia
Su Hyun Park, Sang Hyoung Park
Journal of Gastroenterology and Hepatology.2022; 37(8): 1434. CrossRef
Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α
Jihye Park, Jae Hee Cheon
The Korean Journal of Internal Medicine.2022; 37(5): 895. CrossRef
Inflammatory bowel disease in Korea: epidemiology and pathophysiology
Jung Won Lee, Chang Soo Eun
The Korean Journal of Internal Medicine.2022; 37(5): 885. CrossRef
Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs
Soo-Young Na, You Sun Kim
The Korean Journal of Internal Medicine.2022; 37(5): 906. CrossRef
Clinical Characteristics of Korean Patients with Elderly-Onset Crohn’s Disease: Results from the Prospective CONNECT Study
You Sun Kim, Min Jeong Na, Byong Duk Ye, Jae Hee Cheon, Jong Pil Im, Joo Sung Kim
Gut and Liver.2022; 16(6): 995. CrossRef
Comparison between Pediatric Crohn’s Disease and Ulcerative Colitis at Diagnosis in Korea: Results from a Multicenter, Registry-Based, Inception Cohort Study
Sowon Park, Ben Kang, Seung Kim, Sujin Choi, Hyo Rim Suh, Eun Sil Kim, Ji Hyung Park, Mi Jin Kim, Yon Ho Choe, Yeoun Joo Lee, Jae Hong Park, Eell Ryoo, Hong Koh, Byung-Ho Choe
Gut and Liver.2022; 16(6): 921. CrossRef

7,771 View
689 Download
36 Web of Science
35 Crossref

Original Articles

Inflammatory bowel diseases

The prevalence of sarcopenia and its effect on prognosis in patients with Crohn’s disease: Chan Hyung Lee, Hyuk Yoon, Dong Jun Oh, Jae Min Lee, Yoon Jin Choi, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee, Joo Sung Kim; Intest Res 2020;18(1):79-84. Published online January 30, 2020; DOI: https://doi.org/10.5217/ir.2019.00107

Abstract PDF PubReader ePub

Background/Aims
Crohn’s disease is associated with altered body composition, such as low muscle mass, which can affect clinical outcomes. However, there are few studies regarding the effect of sarcopenia on prognosis of Crohn’s disease. In this study, we evaluated the body composition at the initial diagnosis of Crohn’s disease and analyzed the clinical meaning of sarcopenia.
Methods
We conducted a retrospective review of medical records of patients who were diagnosed as Crohn’s disease and underwent computed tomography within 3 months after diagnosis. Sarcopenia was defined as an L3 skeletal muscle index (SMI) of < 49 cm²/m² for men and < 31 cm²/m² for women. Outcomes such as need for hospitalization, surgery, use of steroids, immunomodulators and biologics were analyzed.
Results
A total of 79 patients (male, 73.4%; mean age, 29.9 years) were included and 40 patients (51%) were diagnosed as sarcopenia. C-reactive protein (CRP) level was correlated with sarcopenia (P= 0.044). Erythrocyte sedimentation rate (ESR) showed a tendency to decrease inversely with SMI (r = –0.320, P= 0.008) and hemoglobin and albumin tended to increase in proportion to SMI (hemoglobin: r = 0.271, P= 0.016 and albumin: r = 0.350, P= 0.002). However, there was no statistically significance in time-to-first-event analysis in aspects of sarcopenia.
Conclusions
Approximately 50% of patients with newly diagnosed as Crohn’s disease had sarcopenia. CRP levels were higher in the sarcopenia group and SMI correlated with ESR, hemoglobin, and albumin. However, none of prognostic values were demonstrated.

Citations

Citations to this article as recorded by

The Relationship Between Intramural Fat Accumulation and Sarcopenia on MR Enterography Exams in Patients with Crohn’s Disease
Oktay Algin, Yasin Celal Güneş, Rasim Eren Cankurtaran, Seniha Corabay, Oyku Tayfur Yurekli
RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren.2025; 197(03): 298. CrossRef
Author’s Reply: Is Sarcopenia More Than Just Low Body Mass?
Ria Minawala, Adam S Faye
Inflammatory Bowel Diseases.2025; 31(4): 1191. CrossRef
Evaluating the role of sarcopenia in adverse clinical outcomes for Crohn’s disease patients: a systematic review and meta-analysis
Othman Saleh, Sakhr Alshwayyat, Muhannad A. L. Hares, Suhaib Shalan, Deya’a Alasmar, Omar Alkurdi, Hamdah Hanifa, Momen Hajali
International Journal of Colorectal Disease.2025;[Epub] CrossRef
Prevalence and outcome of sarcopenia in patients with inflammatory bowel disease: a follow-up study
Vikram Dharap, Devendra Desai, Philip Abraham, Tarun Gupta, Pavan Dhoble, Nirad Mehta, Jagdish Modhe
Intestinal Research.2025;[Epub] CrossRef
New criteria of the Asian working group for sarcopenia: High prevalence of severe sarcopenia in hospitalized patients
Yeon-Hee Han, MinJeong Kim, Jong Hun Kim, Hwan-Jeong Jeong, Seok Tae Lim
Medicine.2025; 104(11): e41912. CrossRef
Sarcopenia and frailty in inflammatory bowel disease: Emerging concepts and evidence
Pardhu B Neelam, Alka Sharma, Vishal Sharma
JGH Open.2024;[Epub] CrossRef
The association between hemoglobin level and sarcopenia in Chinese patients with Crohn’s disease
Nandong Hu, Jingjing Liu, Xifa Gao, Hongye Tang, Jiangchuan Wang, Zicheng Wei, Zhongqiu Wang, Xiaoli Yu, Xiao Chen
BMC Gastroenterology.2024;[Epub] CrossRef
Hepatic Steatosis but Not Fibrosis Is Independently Associated with Poor Outcomes in Patients with Inflammatory Bowel Disease
Hye Kyung Hyun, Hye Won Lee, Jihye Park, Soo Jung Park, Jae Jun Park, Tae Il Kim, Jae Seung Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim, Jae Hee Cheon
Gut and Liver.2024; 18(2): 294. CrossRef
Ultrasound muscle assessment for sarcopenia detection in inflammatory bowel disease: A prospective study
Giacomo Mulinacci, Lorena Pirola, Davide Gandola, Davide Ippolito, Chiara Viganò, Alice Laffusa, Camilla Gallo, Pietro Invernizzi, Silvio Danese, Sara Massironi
United European Gastroenterology Journal.2024; 12(5): 562. CrossRef
Causal associations between autoimmune diseases and sarcopenia-related traits: a bi-directional Mendelian randomization study
Chunlan Chen, Ying He
Frontiers in Genetics.2024;[Epub] CrossRef
The relationship between inflammatory bowel disease and sarcopenia-related traits: a bidirectional two-sample mendelian randomization study
Zhihuang Sun, Guangwei Liu, Jiajia Xu, Xianyu Zhang, Huahua Wei, Guobao Wu, Jian Jiang
Frontiers in Endocrinology.2024;[Epub] CrossRef
Association between sarcopenia and hemoglobin level: a systematic review and meta-analysis
Hui Wang, Ping Lin
Frontiers in Medicine.2024;[Epub] CrossRef
Micronutrient Deficiency and Muscular Status in Inflammatory Bowel Disease
Joonhee Han, Hyun Joo Song, Min Sook Kang, Hogyung Jun, Heung Up Kim, Ki Soo Kang, Donghyoun Lee
Nutrients.2024; 16(21): 3763. CrossRef
Assessment of body composition-related imaging parameters indicative of sarcopenia in Chinese patients with Crohn’s disease: correlation with disease severity and biologic efficacy
Chen Xie
American Journal of Translational Research.2024; 16(10): 5427. CrossRef
Impact of Sarcopenia on Clinical Course of Inflammatory Bowel Disease in Korea
Kwangwoo Nam, Jae Yong Lee, Yousun Ko, Kyung Won Kim, Ho-Su Lee, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byoun, Seung-Jae Myung, Suk-Kyun Yang, Sang Hyoung Park
Digestive Diseases and Sciences.2023; 68(6): 2165. CrossRef
Nutritional Risk and Sarcopenia Features in Patients with Crohn’s Disease: Relation to Body Composition, Physical Performance, Nutritional Questionnaires and Biomarkers
Konstantinos Papadimitriou, Paraskevi Detopoulou, Konstantinos Soufleris, Gavriela Voulgaridou, Despoina Tsoumana, Panagiotis Ntopromireskou, Constantinos Giaginis, Ioanna P. Chatziprodromidou, Maria Spanoudaki, Sousana K. Papadopoulou
Nutrients.2023; 15(16): 3615. CrossRef
Two-year real-world outcome data from a single tertiary centre shows reduced ustekinumab persistence in a non-bio-naïve Crohn’s disease cohort with penetrating disease, -ostomies and sarcopenia
Saskia Inniss, Konstantinos C. Fragkos, Lisa Whitley, Rachel Wimpory, Eleanor Rebello, Ana Lisboa, Tanvi Khetan, Jasmine Hassan, Kate Simpson, Anisha Bhagwanani, Roser Vega, Ioanna Parisi, Paul Harrow, Edward Seward, Sara McCartney, Stuart Bloom, Andrew M
Therapeutic Advances in Chronic Disease.2023;[Epub] CrossRef
Sarcopenia is a negative predictive factor for endoscopic remission in patients with Crohn's disease treated with biologics
Mauro Grova, Federica Crispino, Marcello Maida, Alessandro Vitello, Sara Renna, Angelo Casà, Lorenzo Tesè, Fabio Salvatore Macaluso, Ambrogio Orlando
Digestive and Liver Disease.2023; 55(7): 865. CrossRef
The effect of biological agent on body composition in patients with Crohn’s disease
Eun Jeong Choi, Dong Hoon Baek, Hong Sub Lee, Geun Am Song, Tae Oh Kim, Yong Eun Park, Chang Min Lee, Jong Hoon Lee
BMC Gastroenterology.2023;[Epub] CrossRef
Review article: Putting some muscle into sarcopenia—the pathogenesis, assessment and clinical impact of muscle loss in patients with inflammatory bowel disease
Stephanie L. Gold, Maitreyi Raman, Bruce E. Sands, Ryan Ungaro, João Sabino
Alimentary Pharmacology & Therapeutics.2023; 57(11): 1216. CrossRef
Association between computed tomography‐assessed sarcopenia and mortality in patients with anti‐neutrophil cytoplasmic antibody‐associated vasculitis
Sung Soo Ahn, Yong‐Beom Park, Sang‐Won Lee
International Journal of Rheumatic Diseases.2023; 26(9): 1704. CrossRef
Imaging-based assessment of body composition in patients with Crohn’s disease: a systematic review
Wuli Tang, Gang Xie, Danni Wang, Ting Li, Yitao Ren, Junlin Li, Jiaxing Deng, Kang Li
International Journal of Colorectal Disease.2023;[Epub] CrossRef
Systematic review of sarcopenia in inflammatory bowel disease
Hala Fatani, Adina Olaru, Rebecca Stevenson, Waad Alharazi, Ayman Jafer, Philip Atherton, Matthew Brook, Gordon Moran
Clinical Nutrition.2023; 42(8): 1276. CrossRef
Nutrition, Nutritional Status, Micronutrients Deficiency, and Disease Course of Inflammatory Bowel Disease
Marco Valvano, Annalisa Capannolo, Nicola Cesaro, Gianpiero Stefanelli, Stefano Fabiani, Sara Frassino, Sabrina Monaco, Marco Magistroni, Angelo Viscido, Giovanni Latella
Nutrients.2023; 15(17): 3824. CrossRef
Magnetic Resonance Imaging Can Be Used to Assess Sarcopenia in Children with Newly Diagnosed Crohn’s Disease
Paola Blagec, Sila Sara, Ana Tripalo Batoš, Ivana Trivić Mažuranić, Ana Močić Pavić, Zrinjka Mišak, Iva Hojsak
Nutrients.2023; 15(17): 3838. CrossRef
Key genes of inflammation and Crohn’s disease severity identified via bioinformatics and clinical specimen analysis
Min Lu, Zhirui Zeng, Yongjian Ling, Qinsong Zhong, Zhiliang Mai, Hua Mao, Qian Wang
All Life.2023;[Epub] CrossRef
Research progress on the predictive role of sarcopenia in the course and prognosis of inflammatory bowel disease
Yang Liu, Linglin Tian
PeerJ.2023; 11: e16421. CrossRef
Characteristics of malnutrition according to Global Leadership Initiative on Malnutrition criteria in non-surgical patients with inflammatory bowel disease
Shanshan Huang, Yang Niu, Xiaowei Liu, Zhengye Gu, Aiyue Huang, Jiang Wu
Nutrition.2022; 94: 111514. CrossRef
Nutritional screening and assessment in inflammatory bowel disease
Arshdeep Singh, Catherine Wall, Arie Levine, Vandana Midha, Ramit Mahajan, Ajit Sood
Indian Journal of Gastroenterology.2022; 41(1): 5. CrossRef
Association Between Frailty or Sarcopenia and Adverse Outcomes in Inflammatory Bowel Disease: A Systematic Review
Katherine Bedard, Naheed Rajabali, Puneeta Tandon, Juan G. Abraldes, Farhad Peerani
Gastro Hep Advances.2022; 1(2): 241. CrossRef
Sarcopenia Is More Prevalent Among Inflammatory Bowel Disease Patients Undergoing Surgery and Predicts Progression to Surgery Among Medically Treated Patients
James P Campbell, Levi Teigen, Scott Manski, Brian Blumhof, Flavius F Guglielmo, Raina Shivashankar, Eugenia Shmidt
Inflammatory Bowel Diseases.2022; 28(12): 1844. CrossRef
Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus
Ashwin N Ananthakrishnan, Gilaad G Kaplan, Charles N Bernstein, Kristin E Burke, Paul J Lochhead, Alexa N Sasson, Manasi Agrawal, Jimmy Ho Tuan Tiong, Joshua Steinberg, Wolfgang Kruis, Flavio Steinwurz, Vineet Ahuja, Siew C Ng, David T Rubin, Jean-Frederi
The Lancet Gastroenterology & Hepatology.2022; 7(7): 666. CrossRef
Sarcopenia in Inflammatory Bowel Diseases: Reviewing Past Work to Pave the Path for the Future
Adam S. Faye, Tasnin Khan, Sandhya Cautha, Bharati Kochar
Current Treatment Options in Gastroenterology.2022; 20(3): 250. CrossRef
Personalized medicine in inflammatory bowel disease: Perspectives on Asia
Su Hyun Park, Sang Hyoung Park
Journal of Gastroenterology and Hepatology.2022; 37(8): 1434. CrossRef
Hematopoietic Stem Cell Transplantation in Refractory Crohn’s Disease: Should It Be Considered?
Simon Reider, Lukas Binder, Stefan Fürst, Stefan Hatzl, Andreas Blesl
Cells.2022; 11(21): 3463. CrossRef
Serial Changes in Body Composition and the Association with Disease Activity during Treatment in Patients with Crohn’s Disease
Ji Young Lee, Kyung Won Kim, Yousun Ko, Chi Hyuk Oh, Bo Hyun Kim, Seong Jin Park, Myung-Won You
Diagnostics.2022; 12(11): 2804. CrossRef
Low psoas muscle area is associated with postoperative complications in Crohn’s disease
Yaniv Zager, Saed Khalilieh, Omar Ganaiem, Eli Gorgov, Nir Horesh, Roi Anteby, Uri Kopylov, Harel Jacoby, Yael Dreznik, Assaf Dori, Mordechai Gutman, Avinoam Nevler
International Journal of Colorectal Disease.2021; 36(3): 543. CrossRef
Combination of sarcopenia and high visceral fat predict poor outcomes in patients with Crohn’s disease
Gurasis Boparai, Saurabh Kedia, Devasenathipathy Kandasamy, Raju Sharma, Kumble Seetharama Madhusudhan, Nihar Ranjan Dash, Pabitra Sahu, Sujoy Pal, Peush Sahni, Rajesh Panwar, Sudheer Kumar Vuyyuru, Bhaskar Kante, Davesh P. Yadav, Venigalla Pratap Mouli,
European Journal of Clinical Nutrition.2021; 75(10): 1491. CrossRef
Sarcopenia in Inflammatory Bowel Disease: A Narrative Overview
Amritpal Dhaliwal, Jonathan I. Quinlan, Kellie Overthrow, Carolyn Greig, Janet M. Lord, Matthew J. Armstrong, Sheldon C. Cooper
Nutrients.2021; 13(2): 656. CrossRef
Sarcopenia and Vitamin D Deficiency in Patients with Crohn’s Disease: Pathological Conditions That Should Be Linked Together
Francesco Palmese, Rossella Del Toro, Giulia Di Marzio, Pierluigi Cataleta, Maria Giulia Sama, Marco Domenicali
Nutrients.2021; 13(4): 1378. CrossRef
Pathogenesis of Musculoskeletal Deficits in Children and Adults with Inflammatory Bowel Disease
Lewis Steell, Stuart R. Gray, Richard K. Russell, Jonathan MacDonald, John Paul Seenan, Sze Choong Wong, Daniel R. Gaya
Nutrients.2021; 13(8): 2899. CrossRef
Inflammatory Bowel Disease and Sarcopenia: Its Mechanism and Clinical Importance
Hiroki Nishikawa, Shiro Nakamura, Takako Miyazaki, Kazuki Kakimoto, Shinya Fukunishi, Akira Asai, Shuhei Nishiguchi, Kazuhide Higuchi
Journal of Clinical Medicine.2021; 10(18): 4214. CrossRef
Myostatin and Follistatin—New Kids on the Block in the Diagnosis of Sarcopenia in IBD and Possible Therapeutic Implications
Dorota Skrzypczak, Marzena Skrzypczak-Zielińska, Alicja Ewa Ratajczak, Aleksandra Szymczak-Tomczak, Piotr Eder, Ryszard Słomski, Agnieszka Dobrowolska, Iwona Krela-Kaźmierczak
Biomedicines.2021; 9(10): 1301. CrossRef
Adults with Crohn’s disease exhibit elevated gynoid fat and reduced android fat irrespective of disease relapse or remission
Lisa Dowling, Philip Jakeman, Catherine Norton, Maeve M. Skelly, Hamid Yousuf, Miranda G. Kiernan, Margaret Toomey, Sheila Bowers, Suzanne S. Dunne, J. Calvin Coffey, Colum P. Dunne
Scientific Reports.2021;[Epub] CrossRef
What Determines Good Rehabilitation Recovery in Stroke Patients with very Severe Disability? A Retrospective Cohort Study
Shengjie Zhao, Tong Zhang, Bingjie Li, Zhangwei Wu, Jun Zhao
Journal of Stroke and Cerebrovascular Diseases.2020; 29(10): 105130. CrossRef
Sarcopenia in Autoimmune and Rheumatic Diseases: A Comprehensive Review
Hyo Jin An, Kalthoum Tizaoui, Salvatore Terrazzino, Sarah Cargnin, Keum Hwa Lee, Seoung Wan Nam, Jae Seok Kim, Jae Won Yang, Jun Young Lee, Lee Smith, Ai Koyanagi, Louis Jacob, Han Li, Jae Il Shin, Andreas Kronbichler
International Journal of Molecular Sciences.2020; 21(16): 5678. CrossRef
Diagnosis of malnutrition in patients with gastrointestinal diseases: recent observations from a Global Leadership Initiative on Malnutrition perspective
Tommy Cederholm, Zeljko Krznaric, Matthias Pirlich
Current Opinion in Clinical Nutrition & Metabolic Care.2020; 23(5): 361. CrossRef
Incorporating Frailty in the Treatment Program of Elderly Patients with Gastrointestinal Disease
C. Thompson, S. Taleban
Current Treatment Options in Gastroenterology.2020; 18(4): 635. CrossRef

10,101 View
230 Download
48 Web of Science
48 Crossref

Inflammatory bowel diseases

5-Aminosalicylic acid intolerance is associated with a risk of adverse clinical outcomes and dysbiosis in patients with ulcerative colitis: Shinta Mizuno, Keiko Ono, Yohei Mikami, Makoto Naganuma, Tomohiro Fukuda, Kazuhiro Minami, Tatsuhiro Masaoka, Soichiro Terada, Takeshi Yoshida, Keiichiro Saigusa, Norimichi Hirahara, Hiroaki Miyata, Wataru Suda, Masahira Hattori, Takanori Kanai; Intest Res 2020;18(1):69-78. Published online January 30, 2020; DOI: https://doi.org/10.5217/ir.2019.00084

Abstract PDF Supplementary Material PubReader ePub

Background/Aims
5-Aminosalicylic acid (ASA) causes intolerance reactions in some patients. This study was performed to examine the prognosis of patients with ulcerative colitis (UC) and 5-ASA intolerance, and to evaluate the potential interaction between 5-ASA intolerance and the intestinal microbiota.
Methods
We performed a retrospective cohort study of patients with UC who visited participating hospitals. The primary endpoint was to compare the incidence of hospitalization within 12 months between the 5-ASA intolerance group and the 5-ASA tolerance group. The secondary endpoint was to compare the risk of adverse clinical outcomes after the start of biologics between the 2 groups. We also assessed the correlation between 5-ASA intolerance and microbial change in an independently recruited cohort of patients with UC.
Results
Of 793 patients, 59 (7.4%) were assigned to the 5-ASA intolerance group and 734 (92.5%) were assigned to the 5-ASA tolerance group. The admission rate and incidence of corticosteroid use were significantly higher in the intolerance than tolerance group (P< 0.001). In 108 patients undergoing treatment with anti-tumor necrosis factor biologics, 5-ASA intolerance increased the incidence of additional induction therapy after starting biologics (P< 0.001). The 5-ASA intolerance group had a greater abundance of bacteria in the genera Faecalibacterium, Streptococcus, and Clostridium than the 5-ASA tolerance group (P< 0.05).
Conclusions
In patients with UC, 5-ASA intolerance is associated with a risk of adverse clinical outcomes and dysbiosis. Bacterial therapeutic optimization of 5-ASA administration may be important for improving the prognosis of patients with UC.

Citations

Citations to this article as recorded by

Drug-induced Interstitial Nephritis in a Patient with Ulcerative Colitis Treated with 5-Aminosalicylic Acid
Daichi Hayashi, Tsutomu Nishida, Naoto Osugi, Yasuo Kusunoki, Satoru Okabe, Yoshifumi Fujii, Dai Nakamatsu, Kengo Matsumoto, Masashi Yamamoto, Koji Fukui
Internal Medicine.2024; 63(8): 1081. CrossRef
The impact of 5-aminosalicylates on the efficacy of mesenchymal stem cell therapy in a murine model of ulcerative colitis
Huanhuan Chen, Huimin Wang, XiaoJing Xu, Ya'nan Hu, Jing Su, Dongdong Li, Zimu Li, Shixiang Feng, Jinming Liu, Huanxiang Zhang, Xiaoyan Wang
International Immunopharmacology.2024; 134: 112255. CrossRef
Characteristics of Mucosa-Associated Microbiota in Ulcerative Colitis Patients with 5-Aminosalicylic Acid Intolerance
Hiroshi Matsumoto, Momoyo Sasahira, Tei Tei Go, Shogen Yo, Takehiro Ninomiya, Motoyasu Osawa, Osamu Handa, Eiji Umegami, Ryo Inoue, Akiko Shiotani
Biomedicines.2024; 12(9): 2125. CrossRef
Lithium Coupled with C6-Carboxyl Improves the Efficacy of Oligoguluronate in DSS-Induced Ulcerative Colitis in C57BL/6J Mice
Jiayi Li, Meng Shao, Hao Liu, Peng Guo, Fei Liu, Mingfeng Ma, Quancai Li
Marine Drugs.2024; 22(12): 573. CrossRef
Persistence of newly prescribed 5-aminosalicylic acid in patients with ulcerative colitis: A nationwide comprehensive database study
Tatsuya Noda, Kotaro Kuwaki, Munehito Machida, Yasuyuki Okumura, Yuichi Nishioka, Tomoya Myojin, Tomoaki Imamura, Barry Kweh
PLOS ONE.2024; 19(12): e0316181. CrossRef
Manipulating Microbiota in Inflammatory Bowel Disease Treatment: Clinical and Natural Product Interventions Explored
Mengjie Zhu, Yijie Song, Yu Xu, Hongxi Xu
International Journal of Molecular Sciences.2023; 24(13): 11004. CrossRef
Risk factors for intolerance of oral 5‐aminosalicylic acid preparations in pediatric ulcerative colitis
Naoki Abe, Naomi Iwata, Ryuhei Yasuoka, Daisuke Nishida, Asami Oohara, Haruna Nakaseko, Shiro Sugiura, Shinji Kawabe
Pediatrics International.2023;[Epub] CrossRef
CURRENT STATUS, PROBLEMS AND PROSPECTS OF ULCERATIVE COLITIS MEDICAL CORRECTION (LITERATURE REVIEW)
T. O. Briukhanova, O. A. Nakonechna, O. V Babenko
Bulletin of Problems Biology and Medicine.2023; 1(3): 28. CrossRef
Significance of 5-Aminosalicylic Acid Intolerance in the Clinical Management of Ulcerative Colitis
Yohei Mikami, Junya Tsunoda, Shohei Suzuki, Ichiro Mizushima, Hiroki Kiyohara, Takanori Kanai
Digestion.2023; 104(1): 58. CrossRef
Genetic Background of Mesalamine-induced Fever and Diarrhea in Japanese Patients with Inflammatory Bowel Disease
Kaoru Suzuki, Yoichi Kakuta, Takeo Naito, Tetsuya Takagawa, Hiroyuki Hanai, Hiroshi Araki, Yu Sasaki, Hirotake Sakuraba, Makoto Sasaki, Tadakazu Hisamatsu, Satoshi Motoya, Takayuki Matsumoto, Motoyuki Onodera, Yoh Ishiguro, Hiroshi Nakase, Akira Andoh, Sa
Inflammatory Bowel Diseases.2022; 28(1): 21. CrossRef
Classification and clinical features of adverse drug reactions in patients with ulcerative colitis treated with 5‐aminosalicylate acid: a single-center, observational study
Yuri Tsujii, Tsutomu Nishida, Naoto Osugi, Yoshifumi Fujii, Aya Sugimoto, Dai Nakamatsu, Kaori Mukai, Kengo Matsumoto, Shiro Hayashi, Masashi Yamamoto, Sachiko Nakajima
Scandinavian Journal of Gastroenterology.2022; 57(2): 190. CrossRef
The Prognostic Value of Residual Nonrectal Inflammation in Ulcerative Colitis
Eun Ae Kang
Gut and Liver.2022; 16(3): 487. CrossRef
Personalized medicine in inflammatory bowel disease: Perspectives on Asia
Su Hyun Park, Sang Hyoung Park
Journal of Gastroenterology and Hepatology.2022; 37(8): 1434. CrossRef
Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α
Jihye Park, Jae Hee Cheon
The Korean Journal of Internal Medicine.2022; 37(5): 895. CrossRef
The emerging microbiome‐based approaches to IBD therapy: From SCFAs to urolithin A
Mohammad Rudiansyah, Saade Abdalkareem Jasim, Bakhadir S. Azizov, Vadim Samusenkov, Walid Kamal Abdelbasset, Ghulam Yasin, Hawraa Jabbar Mohammad, Mohammed Abed Jawad, Trias Mahmudiono, Seyed Reza Hosseini‐Fard, Rasoul Mirzaei, Sajad Karampoor
Journal of Digestive Diseases.2022; 23(8-9): 412. CrossRef
Multicenter survey on mesalamine intolerance in patients with ulcerative colitis
Sakiko Hiraoka, Akiko Fujiwara, Tatsuya Toyokawa, Reiji Higashi, Yuki Moritou, Shinjiro Takagi, Kazuhiro Matsueda, Seiyuu Suzuki, Jiro Miyaike, Toshihiro Inokuchi, Masahiro Takahara, Jun Kato, Hiroyuki Okada
Journal of Gastroenterology and Hepatology.2021; 36(1): 137. CrossRef
Enteric-coated gelatin nanoparticles mediated oral delivery of 5-aminosalicylic acid alleviates severity of DSS-induced ulcerative colitis
Anas Ahmad, Md. Meraj Ansari, Rakesh Kumar Mishra, Ajay Kumar, Akshay Vyawahare, Rahul Kumar Verma, Syed Shadab Raza, Rehan Khan
Materials Science and Engineering: C.2021; 119: 111582. CrossRef
Bacteriotherapy for inflammatory bowel disease
Yusuke Yoshimatsu, Yohei Mikami, Takanori Kanai
Inflammation and Regeneration.2021;[Epub] CrossRef
Treatment of inflammatory bowel diseases: focusing on 5-aminosalicylates and immunomodulators
You Sun Kim
Journal of the Korean Medical Association.2021; 64(9): 596. CrossRef
The Communication Between Intestinal Microbiota and Ulcerative Colitis: An Exploration of Pathogenesis, Animal Models, and Potential Therapeutic Strategies
Yu Hu, Zhen Ye, Mingquan Wu, Yingqi She, Linzhen Li, Yujie Xu, Kaihua Qin, Zhipeng Hu, Maoyi Yang, Fating Lu, Qiaobo Ye
Frontiers in Medicine.2021;[Epub] CrossRef
Pharmacogenetics-based personalized treatment in patients with inflammatory bowel disease: A review
Ji Young Chang, Jae Hee Cheon
Precision and Future Medicine.2021; 5(4): 151. CrossRef
5‐aminosalicylate–intolerant patients are at increased risk of colectomy for ulcerative colitis
Shuji Hibiya, Yusuke Matsuyama, Toshimitsu Fujii, Chiaki Maeyashiki, Eiko Saito, Kimiko Ito, Hiromichi Shimizu, Ami Kawamoto, Maiko Motobayashi, Kento Takenaka, Masakazu Nagahori, Masayuki Kurosaki, Tsunehito Yauchi, Kazuo Ohtsuka, Takeo Fujiwara, Ryuichi
Alimentary Pharmacology & Therapeutics.2021; 53(1): 103. CrossRef
Mesalazine allergy and an attempt at desensitization therapy in patients with inflammatory bowel disease
Satohiro Matsumoto, Hirosato Mashima
Scientific Reports.2020;[Epub] CrossRef

8,540 View
355 Download
26 Web of Science
23 Crossref

Review

Novel biomarkers for the diagnosis and prognosis of colorectal cancer: Hyung-Hoon Oh, Young-Eun Joo; Intest Res 2020;18(2):168-183. Published online November 30, 2019; DOI: https://doi.org/10.5217/ir.2019.00080

Abstract PDF PubReader ePub

Colorectal cancer (CRC) is among the most common malignancies and remains a major cause of cancer-related death worldwide. Despite recent advances in surgical and multimodal therapies, the overall survival of advanced CRC patients remains very low. Cancer progression, including invasion and metastasis, is a major cause of death among CRC patients. The underlying mechanisms of action resulting in cancer progression are beginning to unravel. The reported molecular and biochemical mechanisms that might contribute to the phenotypic changes in favor of carcinogenesis include apoptosis inhibition, enhanced tumor cell proliferation, increased invasiveness, cell adhesion perturbations, angiogenesis promotion, and immune surveillance inhibition. These events may contribute to the development and progression of cancer. A biomarker is a molecule that can be detected in tissue, blood, or stool samples to allow the identification of pathological conditions such as cancer. Thus, it would be beneficial to identify reliable and practical molecular biomarkers that aid in the diagnostic and therapeutic processes of CRC. Recent research has targeted the development of biomarkers that aid in the early diagnosis and prognostic stratification of CRC. Despite that, the identification of diagnostic, prognostic, and/or predictive biomarkers remains challenging, and previously identified biomarkers might be insufficient to be clinically applicable or offer high patient acceptability. Here, we discuss recent advances in the development of molecular biomarkers for their potential usefulness in early and less-invasive diagnosis, treatment, and follow-up of CRC.

Citations

Citations to this article as recorded by

Elucidating prognostic significance of purine metabolism in colorectal cancer through integrating data from transcriptomic, immunohistochemical, and single‐cell RNA sequencing analysis
Sungyeon Kim, Myunghee Kang, Soyeon Jeong, Jisup Kim, Kyoung Oh Kim, Won‐Suk Lee, Jeong‐Heum Baek, Jung Ho Kim, Seungyoon Nam
Molecular Oncology.2025;[Epub] CrossRef
Blocking Tumoral Angiogenesis VEGF/VEGFR Pathway: Bevacizumab—20 Years of Therapeutic Success and Controversy
Elena Chitoran, Vlad Rotaru, Daniela-Cristina Stefan, Giuseppe Gullo, Laurentiu Simion
Cancers.2025; 17(7): 1126. CrossRef
The predictive value of endocan as a novel biomarker: an umbrella study on meta-analyses
Sandeep Samethadka Nayak, Daniyal Ameen, Sara Nobakht, Ranjan Nayak, Shrinidhi Vilas Prabhu, Mohammad-Hossein Keivanlou, Soheil Hassanipour, Ehsan Amini-Salehi, Nisarg Thakker
Systematic Reviews.2025;[Epub] CrossRef
Detection of postoperative recurrence in colorectal cancer: Exploring the value of liquid biopsy
V. Kostiuchenko, I. Vynnychenko, Y. Moskalenko, V. Pohorila
Regulatory Mechanisms in Biosystems.2025; 33(1): e25020. CrossRef
ZNF746 plays cardinal roles on colorectal cancer (CRC) cell invasion and migration and regulates mitochondrial dynamics and morphological changes of CRC cells—Role of combined melatonin and 5‐FU regimen
Chi‐Ruei Huang, Yu‐Ting Chu, Chia‐Lo Chang, Hon‐Kan Yip, Hong‐Hwa Chen
Journal of Cellular Biochemistry.2024;[Epub] CrossRef
Anti‐angiogenesis in colorectal cancer therapy
Zhenni Yang, Xuqian Zhang, Xiaozhe Bai, Xiaonan Xi, Wentian Liu, Weilong Zhong
Cancer Science.2024; 115(3): 734. CrossRef
Bioinformatics analysis of markers based on m6A related to prognosis combined with immune invasion of rectal adenocarcinoma
Shunkang Yan, Jiandong Zhang, Lianghe Li, Gang Chen, Zhongsheng Chen, Wei Zhan
Cancer Biomarkers.2024; 40(1): 95. CrossRef
Identification of Hub genes with prognostic values in colorectal cancer by integrated bioinformatics analysis
Shan Li, Ting Li, Yan-Qing Shi, Bin-Jie Xu, Yu-Yong Deng, Xu-Guang Sun
Cancer Biomarkers.2024; 40(1): 27. CrossRef
Exploring the integration of nanotechnology in the development and application of biosensors for enhanced detection and monitoring of colorectal cancer
Ashkan Hajjafari, Soheil Sadr, Abbas Rahdar, Mansour Bayat, Narges Lotfalizadeh, Shiva Dianaty, Arezou Rezaei, Soroush Partovi Moghaddam, Khashayar Hajjafari, Pouria Ahmadi Simab, Zelal Kharaba, Hassan Borji, Sadanand Pandey
Inorganic Chemistry Communications.2024; 164: 112409. CrossRef
The potential role of SNHG16/ miRNA-146a/ TRAF6 signaling pathway in the protective effect of zoledronate against colorectal cancer and associated osteoporosis in mouse model
Amany Helmy Mohamed, Ahmed Noureldin Hassan, Nesma Hussein Abdel hay, Manar Fouad Ahmed, Marwa M. El Sawy, Mohamed M. Sonbol, Reham Hussein Mohamed
International Immunopharmacology.2024; 133: 112125. CrossRef
An Updated Review on Molecular Biomarkers in Diagnosis and Therapy of Colorectal Cancer
Shruthi Nagainallur Ravichandran, Makalakshmi Murali Kumar, Alakesh Das, Antara Banerjee, Suhanya Veronica, Alexander Sun-Zhang, Hong Zhang, Muralidharan Anbalagan, Xiao-Feng Sun, Surajit Pathak
Current Cancer Drug Targets.2024; 24(6): 595. CrossRef
Investigating the biomarker value of circRNAs in the diagnosis of colorectal cancer: a systematic review
Tahereh Latifi-Pakdehi, Ali Khezrian, Amin Doosti-Irani, Saeid Afshar, Ali Mahdavinezhad
Discover Oncology.2024;[Epub] CrossRef
The diagnostic value of serum Ephrin-A1 in patients with colorectal cancer
Qi-Xin Su, Ze-Jun Zheng, Ying-Hua Xie, Ling-Yu Chu, Yi-Wei Lin, Yin-Qiao Liu, Xin-Xin Li, Yu-Hui Peng, Yi-Wei Xu, Jian-Jun Xie
Scientific Reports.2024;[Epub] CrossRef
Predictive Genetic Biomarkers for the Development of Peritoneal Metastases in Colorectal Cancer
Danique J. I. Heuvelings, Anne G. W. E. Wintjens, Laura Moonen, Sanne M. E. Engelen, Ignace H. J. T. de Hingh, Liselot B. Valkenburg-van Iersel, Marcel den Dulk, Jan Beckervordersandforth, Sharon G. M. Thijssen, Daphne J. G. Leunissen, Laurents P. S. Stas
International Journal of Molecular Sciences.2023; 24(16): 12830. CrossRef
A guide to mass spectrometric analysis of extracellular vesicle proteins for biomarker discovery
Iqbal Jalaludin, David M. Lubman, Jeongkwon Kim
Mass Spectrometry Reviews.2023; 42(2): 844. CrossRef
Comment on " Positive fecal immunochemical test results are associated with non-colorectal cancer mortality"
Yong Eun Park
The Korean Journal of Internal Medicine.2023; 38(2): 264. CrossRef
Simple Isothermal and Label-Free Strategy for Colorectal Cancer Potential Biomarker miR-625-5p Detection
Yifei Chen, Lizhen Ye, Hui Chen, Tingting Fan, Cheng Qiu, Yan Chen, Yuyang Jiang
Biosensors.2023; 13(1): 78. CrossRef
DNA and RNA Alterations Associated with Colorectal Peritoneal Metastases: A Systematic Review
Danique J. I. Heuvelings, Anne G. W. E. Wintjens, Julien Luyten, Guus E. W. A. Wilmink, Laura Moonen, Ernst-Jan M. Speel, Ignace H. J. T. de Hingh, Nicole D. Bouvy, Andrea Peeters
Cancers.2023; 15(2): 549. CrossRef
The diagnostic significance of CDH17-positive circulating tumor cells in patients with colorectal cancer
Xiao Meng Pei, Heong Ting Wong, Simon Siu Man Ng, Wing Wa Leung, Yee Ni Wong, Hin Fung Tsang, Amanda Kit Ching Chan, Yin Kwan Evelyn Wong, Allen Chi Shing Yu, Aldrin Kay Yuen Yim, William Chi Shing Cho, John Kwok Cheung Chan, Kwong Fai Wong, John M Luk, W
Expert Review of Molecular Diagnostics.2023; 23(2): 171. CrossRef
lncRNA HCG11 Promotes Colorectal Cancer Cell Malignant Behaviors via Sponging miR-26b-5p
Song Guo, Bingtan Song, Lin Li, Hesheng Li, Tao Yang, Lianmeng Cao, Jian Wang, Fu Wang
Journal of Immunology Research.2023; 2023: 1. CrossRef
Ferroptosis open a new door for colorectal cancer treatment
Hong Liang, Xia He, Yitong Tong, Niuniu Bai, Yushu Pu, Ke Han, Yi Wang
Frontiers in Oncology.2023;[Epub] CrossRef
Novel biomarkers used for early diagnosis and tyrosine kinase inhibitors as targeted therapies in colorectal cancer
Huafeng Jiang, Senjun Zhou, Gang Li
Frontiers in Pharmacology.2023;[Epub] CrossRef
Polymeric nanoparticles approach and identification and characterization of novel biomarkers for colon cancer
Devesh u kapoor, Rahul Garg, Mansi Gaur, Bhupendra G. Prajapati, Gyan Agrawal, Sankha Bhattacharya, Gehan M. Elossaily
Results in Chemistry.2023; 6: 101167. CrossRef
Expression of an oxysterol-metabolizing enzyme in colorectal cancer and its relation to tumor cell behavior and prognosis
Ki-Hyun Kim, Young-Lan Park, Sun-Young Park, Young-Eun Joo
Pathology - Research and Practice.2023; 251: 154875. CrossRef
Recent Developments in Diagnostic and Prognostic Biomarkers for Colorectal Cancer: A Narrative Review
Nefeli Giannopoulou, Constantina Constantinou
Oncology.2023; 101(10): 675. CrossRef
Diagnostic value of serum procalcitonin and C-reactive protein in discriminating between bacterial and nonbacterial colitis: a retrospective study
Jae Yong Lee, So Yeon Lee, Yoo Jin Lee, Jin Wook Lee, Jeong Seok Kim, Ju Yup Lee, Byoung Kuk Jang, Woo Jin Chung, Kwang Bum Cho, Jae Seok Hwang
Journal of Yeungnam Medical Science.2023; 40(4): 388. CrossRef
IDENTIFICATION AND FUNCTIONAL ANALYSIS OF microRNA AS PROSPECTIVE PROGNOSTIC MARKERS OF COLORECTAL CANCER
S.V. Maliborska, T.V. Zadvornyi
Oncology.2023; 25(3): 207. CrossRef
PBK Enhances Cellular Proliferation With Histone H3 Phosphorylation and Suppresses Migration and Invasion With CDH1 Stabilization in Colorectal Cancer
Akira Koshino, Aya Nagano, Akinobu Ota, Toshinori Hyodo, Akane Ueki, Masayuki Komura, Akane Sugimura-Nagata, Masahide Ebi, Naotaka Ogasawara, Kenji Kasai, Yoshitaka Hosokawa, Kunio Kasugai, Satoru Takahashi, Shingo Inaguma
Frontiers in Pharmacology.2022;[Epub] CrossRef
Medicina de precisión: rol de la anatomía patológica en diagnóstico y tratamiento personalizado
Tania S. Quiroz, Facundo Las Heras
Revista Médica Clínica Las Condes.2022; 33(1): 36. CrossRef
Immune profile by multiplexed immunohistochemistry associated with recurrence after chemoradiation in rectal cancer
Seung Wook Hong, Seohyun Lee, Yun Jae Kim, Soyeon Ahn, In Ja Park, Seung‐Mo Hong, Sung Wook Hwang, Sang Hyoung Park, Dong‐Hoon Yang, Byong Duk Ye, Jeong‐Sik Byeon, Suk‐Kyun Yang, Jaeil Kim, Sang‐Yeob Kim, Seung‐Jae Myung
Journal of Gastroenterology and Hepatology.2022; 37(3): 542. CrossRef
SPATA18 Expression Predicts Favorable Clinical Outcome in Colorectal Cancer
Akane Sugimura-Nagata, Akira Koshino, Kazuhiro Nagao, Aya Nagano, Masayuki Komura, Akane Ueki, Masahide Ebi, Naotaka Ogasawara, Toyonori Tsuzuki, Kenji Kasai, Satoru Takahashi, Kunio Kasugai, Shingo Inaguma
International Journal of Molecular Sciences.2022; 23(5): 2753. CrossRef
Osteoporosis Is Associated with an Increased Risk of Colorectal Adenoma and High-Risk Adenoma: A Retrospective, Multicenter, Cross-Sectional, Case-Control Study
Ji Hyung Nam, Myung Koh, Hyoun Woo Kang, Kum Hei Ryu, Dong Seok Lee, Su Hwan Kim, Dong Kee Jang, Ji Bong Jeong, Ji Won Kim, Kook Lae Lee, Dong Jun Oh, Yun Jeong Lim, Seong-Joon Koh, Jong Pil Im, Joo Sung Kim
Gut and Liver.2022; 16(2): 269. CrossRef
The Complete Loss of p53 Expression Uniquely Predicts Worse Prognosis in Colorectal Cancer
Kazuhiro Nagao, Akira Koshino, Akane Sugimura-Nagata, Aya Nagano, Masayuki Komura, Akane Ueki, Masahide Ebi, Naotaka Ogasawara, Toyonori Tsuzuki, Kenji Kasai, Satoru Takahashi, Kunio Kasugai, Shingo Inaguma
International Journal of Molecular Sciences.2022; 23(6): 3252. CrossRef
Risk of Metachronous Colorectal Advanced Neoplasia and Cancer in Patients With 3–4 Nonadvanced Adenomas at Index Colonoscopy: A Systematic Review and Meta-Analysis
Suyeon Park, Seong Ran Jeon, Hyun Gun Kim, Yunho Jung, Min-Seob Kwak, Su Young Kim, Jong Wook Kim, Seung-Joo Nam, Eun Hye Oh, Seon-Young Park, Soo-Kyung Park, Jeong-Sik Byeon, Sun-Jin Boo, Dong Hoon Baek, Soon Man Yoon, Jaeyoung Chun, Jooyoung Lee, Miyoun
American Journal of Gastroenterology.2022; 117(4): 588. CrossRef
MicroRNA Expression Profiling Predicts Nodal Status and Disease Recurrence in Patients Treated with Curative Intent for Colorectal Cancer
Matthew G. Davey, Gerard Feeney, Heidi Annuk, Maxwell Paganga, Emma Holian, Aoife J. Lowery, Michael J. Kerin, Nicola Miller
Cancers.2022; 14(9): 2109. CrossRef
Tumor-Suppressive Effect of Metformin via the Regulation of M2 Macrophages and Myeloid-Derived Suppressor Cells in the Tumor Microenvironment of Colorectal Cancer
Joyeon Kang, Doyeon Lee, Kyoung Jin Lee, Jaepil Eric Yoon, Ji-Hee Kwon, Yoojeong Seo, Janghyun Kim, Shin Young Chang, Jihye Park, Eun Ae Kang, Soo Jung Park, Jae Jun Park, Jae Hee Cheon, Tae Il Kim
Cancers.2022; 14(12): 2881. CrossRef
The Role of Long Non-Coding RNAs in Epithelial-Mesenchymal Transition-Related Signaling Pathways in Prostate Cancer
Dexin Shen, Hongwei Peng, Caixia Xia, Zhao Deng, Xi Tong, Gang Wang, Kaiyu Qian
Frontiers in Molecular Biosciences.2022;[Epub] CrossRef
New Insights into Bile Acids Related Signaling Pathways in the Onset of Colorectal Cancer
Cristiana Caliceti, Angela Punzo, Alessia Silla, Patrizia Simoni, Giulia Roda, Silvana Hrelia
Nutrients.2022; 14(14): 2964. CrossRef
An integrative transcriptome analysis reveals potential predictive, prognostic biomarkers and therapeutic targets in colorectal cancer
Pouria Samadi, Meysam Soleimani, Fatemeh Nouri, Fatemeh Rahbarizadeh, Rezvan Najafi, Akram Jalali
BMC Cancer.2022;[Epub] CrossRef
Crosstalk between mucosal microbiota, host gene expression, and sociomedical factors in the progression of colorectal cancer
Namjoo Kim, Jeong-An Gim, Beom Jae Lee, Byung il Choi, Hee Sook Yoon, Seung Han Kim, Moon Kyung Joo, Jong-Jae Park, Chungyeul Kim
Scientific Reports.2022;[Epub] CrossRef
LncRNA GAS6-AS1 facilitates tumorigenesis and metastasis of colorectal cancer by regulating TRIM14 through miR-370-3p/miR-1296-5p and FUS
Qing Chen, Lin Zhou, De Ma, Juan Hou, Yuxin Lin, Jie Wu, Min Tao
Journal of Translational Medicine.2022;[Epub] CrossRef
Associations of C‑X‑C motif chemokine ligands 1/2/8/13/14 with clinicopathological features and survival profile in patients with colorectal cancer
Xiaofan Luo, Jiandong Tai, Yuhang Zhao, Pingwei Zhao, Di Sun, Lei Wang
Oncology Letters.2022;[Epub] CrossRef
Artificial intelligence-based colorectal polyp histology prediction using narrow-band image-magnifying colonoscopy: a stepping stone for clinical practice
Ji Young Chang
Clinical Endoscopy.2022; 55(5): 699. CrossRef
Clinical applications and optimization of patient-derived organoids in intestinal diseases
Tae Il Kim
Organoid.2022; 2: e22. CrossRef
Novel laboratory biomarkers in colorectal cancer management
Marija Gegovska, Marija Hiljadnikova-Bajro
Macedonian Pharmaceutical Bulletin.2022; 68(03): 333. CrossRef
Higher ETV5 Expression Associates With Poor 5-Florouracil-Based Adjuvant Therapy Response in Colon Cancer
Anil K. Giri
Frontiers in Pharmacology.2021;[Epub] CrossRef
Cell-to-Cell Communication by Host-Released Extracellular Vesicles in the Gut: Implications in Health and Disease
Natalia Diaz-Garrido, Cecilia Cordero, Yenifer Olivo-Martinez, Josefa Badia, Laura Baldomà
International Journal of Molecular Sciences.2021; 22(4): 2213. CrossRef
High phospho‐histone H3 expression uniquely predicts favorable survival among four markers of cellular proliferation in colorectal cancer
Akira Koshino, Satoshi Inoue, Akane Sugimura‐Nagata, Takeshi Nishiyama, Hideki Murakami, Hideaki Ito, Miho Riku, Akihito Inoko, Masahide Ebi, Naotaka Ogasawara, Toyonori Tsuzuki, Kunio Kasugai, Kenji Kasai, Shingo Inaguma
Pathology International.2021; 71(5): 316. CrossRef
Editorial Comment on High phospho‐histone H3 expression uniquely predicts favorable survival among four markers of cellular proliferation in colorectal cancer
Hiroshi Kijima
Pathology International.2021; 71(5): 325. CrossRef
Correlation of CD47 Expression with Adverse Clinicopathologic Features and an Unfavorable Prognosis in Colorectal Adenocarcinoma
Hyunsung Kim, Seungyun Jee, Yeseul Kim, Jongmin Sim, Seongsik Bang, Hwang Kyu Son, Hosub Park, Jaekyung Myung, Young Hyeh Ko, Seung Sam Paik
Diagnostics.2021; 11(4): 668. CrossRef
A Disintegrin and Metalloprotease 12 Promotes Tumor Progression by Inhibiting Apoptosis in Human Colorectal Cancer
Young-Lan Park, Sun-Young Park, Hyung-Hoon Oh, Min-Woo Chung, Ji-Yun Hong, Ki-Hyun Kim, Dae-Seong Myung, Sung-Bum Cho, Wan-Sik Lee, Hyun-Soo Kim, Young-Eun Joo
Cancers.2021; 13(8): 1927. CrossRef
Occurence of RAS reversion in metastatic colorectal cancer patients treated with bevacizumab
Samantha Epistolio, Marco Cefalì, Paolo Spina, Francesca Molinari, Alessandra Movilia, Massimiliano Cergnul, Luca Mazzucchelli, Sara De Dosso, Milo Frattini, Piercarlo Saletti
Oncotarget.2021; 12(11): 1046. CrossRef
Use of Antiplatelet Agents Decreases the Positive Predictive Value of Fecal Immunochemical Tests for Colorectal Cancer but Does Not Affect Their Sensitivity
Yoonsuk Jung, Eui Im, Jinhee Lee, Hyeah Lee, Changmo Moon
Journal of Personalized Medicine.2021; 11(6): 497. CrossRef
Multi-omics analyses of human colorectal cancer revealed three mitochondrial genes potentially associated with poor outcomes of patients
Wei Zhang, Liewen Lin, Ligang Xia, Wanxia Cai, Weier Dai, Chang Zou, Lianghong Yin, Donge Tang, Yong Xu, Yong Dai
Journal of Translational Medicine.2021;[Epub] CrossRef
High expression of DNA damage-inducible transcript 4 (DDIT4) is associated with advanced pathological features in the patients with colorectal cancer
Fahimeh Fattahi, Leili Saeednejad Zanjani, Zohreh Habibi Shams, Jafar Kiani, Mitra Mehrazma, Mohammad Najafi, Zahra Madjd
Scientific Reports.2021;[Epub] CrossRef
Predictors of clinical outcomes of self-expandable metal stent treatment for malignant colorectal obstruction
Bora Han, Ji-Yun Hong, Eun Myung, Hyung-Hoon Oh, Hee-Chan Yang, Sang-Wook Kim, Jun Lee, Seong-Jung Kim, Yeom-Dong Han, Geom-Seok Seo, Gun-Young Hong, Ho-Dong Kim, Hyun-Soo Kim, Young-Eun Joo
Medicine.2021; 100(27): e26616. CrossRef
Risk-stratified colorectal cancer screening for optimal use of colonoscopy resources
Dong-Hoon Yang
The Korean Journal of Internal Medicine.2021; 36(4): 839. CrossRef
LncRNA AFAP1-AS1 Promotes the Progression of Colorectal Cancer through miR-195-5p and WISP1
Yongsheng Li, Zhongpeng Zhu, Xiaokun Hou, Yongjun Sun, Muhammad Wasim Khan
Journal of Oncology.2021; 2021: 1. CrossRef
RNA-sequencing identification and validation of genes differentially expressed in high-risk adenoma, advanced colorectal cancer, and normal controls
Namjoo Kim, Jeong-An Gim, Beom Jae Lee, Byung il Choi, Seung Bin Park, Hee Sook Yoon, Sang Hee Kang, Seung Han Kim, Moon Kyung Joo, Jong-Jae Park, Chungyeul Kim, Han-Kyeom Kim
Functional & Integrative Genomics.2021; 21(3-4): 513. CrossRef
Overview of serum and tissue markers in colorectal cancer: a primer for radiologists
Apurva Bonde, Daniel A. Smith, Elias Kikano, Jennifer M. Yoest, Sree H. Tirumani, Nikhil H. Ramaiya
Abdominal Radiology.2021; 46(12): 5521. CrossRef
Single-cell transcriptomics reveal DHX9 in mature B cell as a dynamic network biomarker before lymph node metastasis in CRC
Huisheng Liu, JiaYuan Zhong, JiaQi Hu, ChongYin Han, Rui Li, XueQing Yao, ShiPing Liu, Pei Chen, Rui Liu, Fei Ling
Molecular Therapy - Oncolytics.2021; 22: 495. CrossRef
Faecal Diagnostic Biomarkers for Colorectal Cancer
Andrea Cruz, Carla M. Carvalho, Alexandra Cunha, Anais Crespo, Águeda Iglesias, Laura García-Nimo, Paulo P. Freitas, Joaquín Cubiella
Cancers.2021; 13(21): 5568. CrossRef
Clinicopathologic and prognostic implications of Golgi Phosphoprotein 3 in colorectal cancer: A meta-analysis
Tao Wang, Jiandong Fei, Shuangfa Nie, Ajay Goel
PLOS ONE.2021; 16(11): e0260035. CrossRef
Detection of Microsatellite Instability in Colorectal Cancer Patients With a Plasma-Based Real-Time PCR Analysis
Namjoo Kim, Sung Min Kim, Beom Jae Lee, Byung il Choi, Hee Sook Yoon, Sang Hee Kang, Seung Han Kim, Moon Kyung Joo, Jong-Jae Park, Chungyeul Kim
Frontiers in Pharmacology.2021;[Epub] CrossRef
Identification of Whole-Serum Glycobiomarkers for Colorectal Carcinoma Using Reverse-Phase Lectin Microarray
Tomas Bertok, Aniko Bertokova, Eduard Jane, Michal Hires, Juvissan Aguedo, Maria Potocarova, Ludovit Lukac, Alica Vikartovska, Peter Kasak, Lubor Borsig, Jan Tkac
Frontiers in Oncology.2021;[Epub] CrossRef
LncRNA PTTG3P Sponge Absorbs microRNA-155-5P to Promote Metastasis of Colorectal Cancer

Ning Liu, Lei Dou, Xinxin Zhang
OncoTargets and Therapy.2020; Volume 13: 5283. CrossRef

15,855 View
716 Download
79 Web of Science
66 Crossref

Original Articles

IBD

Long-term prognosis of Japanese patients with biologic-naïve Crohn’s disease treated with anti-tumor necrosis factor-α antibodies: Rintaro Moroi, Katsuya Endo, Katsutoshi Yamamoto, Takeo Naito, Motoyuki Onodera, Masatake Kuroha, Yoshitake Kanazawa, Tomoya Kimura, Yoichi Kakuta, Atsushi Masamune, Yoshitaka Kinouchi, Tooru Shimosegawa; Intest Res 2019;17(1):94-106. Published online December 3, 2018; DOI: https://doi.org/10.5217/ir.2018.00048

Abstract PDF Supplementary Material PubReader ePub

Background/Aims
Few reports have described the long-term treatment outcomes of the anti-tumor necrosis factor-α antibody for Japanese Crohn’s disease (CD) patients. The aim of this study was to evaluate them and clarify the clinical factors that affect the long-term prognosis of the anti-tumor necrosis factor-α treatments.
Methods
This was a retrospective, observational, single-center cohort study. Japanese CD patients treated with either infliximab or adalimumab as a first-line therapy were analyzed. The cumulative retention rates of the biologics, relapse-free survival, and surgery-free survival were analyzed using Kaplan-Meier methods. The clinical factors associated with the long-term outcomes were estimated by both the log-rank test and Cox proportional hazard model.
Results
The cumulative retention rate was significantly higher in the group with a concomitant elemental diet of ≥900 kcal/day, baseline C-reactive protein (CRP) levels <2.6 mg/dL, and baseline serum albumin levels ≥3.5 g/dL, respectively. The baseline serum albumin levels were also associated with both relapse-free and surgery-free survival. The lack of concomitant use of an elemental diet ≥900 kcal/day was identified as the only independent risk factor for the withdrawal of the biologics.
Conclusions
Baseline CRP levels and serum albumin levels could affect the long-term outcomes in CD patients. Concomitant elemental diet of ≥900 kcal/day could have a positive influence on clinical treatment course.

Citations

Citations to this article as recorded by

Nutrition, Nutritional Status, Micronutrients Deficiency, and Disease Course of Inflammatory Bowel Disease
Marco Valvano, Annalisa Capannolo, Nicola Cesaro, Gianpiero Stefanelli, Stefano Fabiani, Sara Frassino, Sabrina Monaco, Marco Magistroni, Angelo Viscido, Giovanni Latella
Nutrients.2023; 15(17): 3824. CrossRef
Long-term clinical and real-world experience with Crohn’s disease treated with anti-tumor necrosis factor-α antibodies
Haruka Otake, Satohiro Matsumoto, Hirosato Mashima
Intestinal Research.2022; 20(4): 464. CrossRef
Natural history of inflammatory bowel disease: a comparison between the East and the West
Eun Mi Song, Suk-Kyun Yang
Intestinal Research.2022; 20(4): 418. CrossRef
Treatment of inflammatory bowel diseases: focusing on biologic agents and new therapies
Hyo Yeop Song, Geom Seog Seo
Journal of the Korean Medical Association.2021; 64(9): 605. CrossRef
C-reactive protein is associated with postoperative outcomes in patients with intestinal Behçet’s disease
Eun Ae Kang, Jung Won Park, Yehyun Park, Soo Jung Park, Tae Il Kim, Won Ho Kim, Min Soo Cho, Jae Hee Cheon
BMC Gastroenterology.2021;[Epub] CrossRef
Pharmacogenetics-based personalized treatment in patients with inflammatory bowel disease: A review
Ji Young Chang, Jae Hee Cheon
Precision and Future Medicine.2021; 5(4): 151. CrossRef
Efficacy of enteral nutrition in patients with Crohn’s disease on maintenance anti-TNF-alpha antibody therapy: a meta-analysis
Fumihito Hirai, Teruyuki Takeda, Yasumichi Takada, Masahiro Kishi, Tsuyoshi Beppu, Noritaka Takatsu, Masaki Miyaoka, Takashi Hisabe, Kenshi Yao, Tosiharu Ueki
Journal of Gastroenterology.2020; 55(2): 133. CrossRef
TL1A (TNFSF15) genotype affects the long‐term therapeutic outcomes of anti‐TNFα antibodies for Crohn's disease patients
Katsuya Endo, Yoichi Kakuta, Rintaro Moroi, Katsutoshi Yamamoto, Hisashi Shiga, Masatake Kuroha, Takeo Naito, Yoshitaka Kinouchi, Atsushi Masamune
JGH Open.2020; 4(6): 1108. CrossRef

7,973 View
244 Download
8 Web of Science
8 Crossref

IBD

Magnetic resonance enterography predicts the prognosis of Crohn's disease: Ji Hoon Lee, Yong Eun Park, Nieun Seo, Hyun Jung Lee, Soo Jung Park, Tae Il Kim, Won Ho Kim, Joon Seok Lim, Jae Hee Cheon; Intest Res 2018;16(3):445-457. Published online July 27, 2018; DOI: https://doi.org/10.5217/ir.2018.16.3.445

Abstract PDF PubReader ePub

Background/Aims

Magnetic resonance enterography (MRE) has emerged as an important tool in the diagnosis and follow-up of Crohn's disease (CD). The aim of this study was to evaluate whether MRE findings could predict the prognosis of CD.

Methods

In this retrospective study, a total of 173 patients with clinical remission of CD (n=61) or active CD (n=112) were identified. The outcomes of clinical relapse, admission, surgery, and need for other medications according to the MRE findings were evaluated.

Results

The presence of active inflammation on MRE was observed in 93 (83%) patients with clinically active CD and in 44 (72.1%) patients with clinical remission of CD, without a statistically significant difference (P=0.091). In multivariate analysis, active inflammation on MRE increased the risk for clinical relapse (hazard ratio [HR], 6.985; 95% confidence interval [CI], 1.024–47.649) in patients with clinical remission of CD. In patients with clinically active CD, active inflammation on MRE increased the risk for CD-related hospitalization (HR, 2.970; 95% CI, 1.006–8.772).

Conclusions

The presence of active inflammation on MRE was significantly associated with poor prognosis both in patients with clinical remission of CD and in those with active CD.

Citations

Citations to this article as recorded by

The Spectrum of Magnetic Resonance Enterography Findings and the Role of Diffusion-Weighted Imaging in Patients with Active Crohn’s Disease
Arvin Arian, Ghazal Roostaei, Seyede Sahel Rasoulighasemlouei, Foroogh Alborzi Avanaki, Nasser Ebrahimi Daryani
Middle East Journal of Digestive Diseases.2024; 16(1): 23. CrossRef
Distribution of small bowel involvement and its association with clinical outcomes in patients with Crohn’s disease
Jin Park, Hae Young Kim, Yoon Jin Lee, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee
Medicine.2023; 102(40): e35040. CrossRef
Combined Endoscopic and Radiologic Healing Is Associated With a Better Prognosis Than Endoscopic Healing Only in Patients With Crohn's Disease Receiving Anti-TNF Therapy
Kyunghwan Oh, Eun Hye Oh, Soo Min Noh, Seong Ho Park, Nayoung Kim, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Byong Duk Ye
Clinical and Translational Gastroenterology.2022; 13(1): e00442. CrossRef
MR Enterography in Crohnʼs Disease: Comparison of Contrast Imaging with Diffusion-weighted Imaging and a special Form of Color Coding
Maja Jakob, Maik Backes, Christian Schaefer, Joerg Albert, Angela Geissler
RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren.2022; 194(10): 1119. CrossRef
Crohn’s disease at radiological imaging: focus on techniques and intestinal tract
Giuseppe Cicero, Silvio Mazziotti
Intestinal Research.2021; 19(4): 365. CrossRef
Radiological Response Is Associated with Better Outcomes and Should Be Considered a Therapeutic Target in Crohn’s Disease
Eléonore Hallé, Mustapha Azahaf, Nicolas Duveau, Thomas Lambin, Maria Nachury, Julien Branche, Romain Gérard, Clémentine Lauriot Dit Prevost, Pauline Wils, Pierre Desreumaux, Olivier Ernst, Benjamin Pariente
Digestive Diseases and Sciences.2020; 65(9): 2664. CrossRef
Magnetic Resonance Enterography and Capsule Endoscopy in Patients Undergoing Patency Capsule for the Evaluation of Small Bowel Crohn’s Disease: A Korean Clinical Experience
Hyun Seok Lee, Yun Jeong Lim, Jin-Hee Jung, Ji Hyung Nam, Junseok Park, Sun Hyung Kang, Ki Bae Kim, Hoon Jai Chun
Gastroenterology Research and Practice.2020; 2020: 1. CrossRef
Beyond Crohn Disease
Michael S. Furman, Edward Y. Lee
Radiologic Clinics of North America.2020; 58(3): 517. CrossRef
Mucosal healing in Crohn’s disease: new insights
Salvatore Cucchiara, Giulia D’Arcangelo, Sara Isoldi, Marina Aloi, Laura Stronati
Expert Review of Gastroenterology & Hepatology.2020; 14(5): 335. CrossRef
Changes in the Management of Patients with Crohn’s Disease Based on Magnetic Resonance Enterography Patterns
Evelyn Sayuri S. Chinem, Barbara C. Esberard, Andre da L. Moreira, Tatiana G. Barbassa, Guilherme M. da Cunha, Antonio Jose de V. Carneiro, Heitor S. de Souza, Ana Teresa P. Carvalho
Gastroenterology Research and Practice.2019; 2019: 1. CrossRef

7,739 View
106 Download
9 Web of Science
10 Crossref

Statement

IBD

Predicting outcomes to optimize disease management in inflammatory bowel disease in Japan: their differences and similarities to Western countries: Taku Kobayashi, Tadakazu Hisamatsu, Yasuo Suzuki, Haruhiko Ogata, Akira Andoh, Toshimitsu Araki, Ryota Hokari, Hideki Iijima, Hiroki Ikeuchi, Yoh Ishiguro, Shingo Kato, Reiko Kunisaki, Takayuki Matsumoto, Satoshi Motoya, Masakazu Nagahori, Shiro Nakamura, Hiroshi Nakase, Tomoyuki Tsujikawa, Makoto Sasaki, Kaoru Yokoyama, Naoki Yoshimura, Kenji Watanabe, Miiko Katafuchi, Mamoru Watanabe, Toshifumi Hibi; Intest Res 2018;16(2):168-177. Published online April 30, 2018; DOI: https://doi.org/10.5217/ir.2018.16.2.168

Abstract PDF PubReader ePub

Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is a chronic inflammatory disease of the gastrointestinal tract, with increasing prevalence worldwide. IBD Ahead is an international educational program that aims to explore questions commonly raised by clinicians about various areas of IBD care and to consolidate available published evidence and expert opinion into a consensus for the optimization of IBD management. Given differences in the epidemiology, clinical and genetic characteristics, management, and prognosis of IBD between patients in Japan and the rest of the world, this statement was formulated as the result of literature reviews and discussions among Japanese experts as part of the IBD Ahead program to consolidate statements of factors for disease prognosis in IBD. Evidence levels were assigned to summary statements in the following categories: disease progression in CD and UC; surgery, hospitalization, intestinal failure, and permanent stoma in CD; acute severe UC; colectomy in UC; and colorectal carcinoma and dysplasia in IBD. The goal is that this statement can aid in the optimization of the treatment strategy for Japanese patients with IBD and help identify high-risk patients that require early intervention, to provide a better long-term prognosis in these patients.

Citations

Citations to this article as recorded by

Precision medicine in inflammatory bowel diseases
Ashwin N. Ananthakrishnan
Intestinal Research.2024; 22(1): 8. CrossRef
Impact of Concomitant Prescriptions and Lifestyle Factors on the Initial Course of Newly Diagnosed Inflammatory Bowel Disease
Hiromu Morikubo, Takayoshi Nagahama, Katsuhiko Nagai, Hajime Yamazaki, Taku Kobayashi
Inflammatory Intestinal Diseases.2024; 9(1): 260. CrossRef
A Retrospective Cohort Study of Clinical Features and Treatment Patterns With Ustekinumab in Patients With Crohn Disease Utilizing a Health Care Database in Japan
Yanfang Liu, Choo Hua Goh, Hong Qiu, Kuan-Chih Huang, Hsingwen Chung, Carine Saadoun
Annals of Pharmacotherapy.2023; 57(9): 1053. CrossRef
Residual Short-Segment Distal Inflammation Has No Significant Impact on the Major Relapse of Extensive Ulcerative Colitis
Kunio Asonuma, Taku Kobayashi, Masaru Nakano, Shintaro Sagami, Hiroki Kiyohara, Mao Matsubayashi, Hiromu Morikubo, Yusuke Miyatani, Shinji Okabayashi, Hajime Yamazaki, Yuichiro Kuroki, Toshifumi Hibi
Inflammatory Bowel Diseases.2022; 28(2): 200. CrossRef
Intestinal cancer in patients with Crohn's disease: A systematic review and meta‐analysis
Motoi Uchino, Hiroki Ikeuchi, Keisuke Hata, Tomohiro Minagawa, Yuki Horio, Ryuichi Kuwahara, Shiro Nakamura, Kenji Watanabe, Masayuki Saruta, Toshimitsu Fujii, Taku Kobayashi, Ken Sugimoto, Fumihito Hirai, Motohiro Esaki, Sakiko Hiraoka, Katsuyoshi Matsuo
Journal of Gastroenterology and Hepatology.2021; 36(2): 329. CrossRef
MR-enterography in Crohn’s disease: what MRE mural parameters are associated to one-year therapeutic management outcome?
Pier Paolo Mainenti, Fabiana Castiglione, Antonio Rispo, Ettore Laccetti, Salvatore Guarino, Valeria Romeo, Anna Testa, Leonardo Pace, Simone Maurea
The British Journal of Radiology.2021;[Epub] CrossRef
Incidence and Outcomes of Perianal Disease in an Asian Population with Crohn’s Disease: A Nationwide Population-Based Study
Eun Mi Song, Ho-Su Lee, Ye-Jee Kim, Eun Hye Oh, Nam Seok Ham, Jeongseok Kim, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Jong Lyul Lee, Yong Sik Yoon, Chang Sik Yu, Suk-Kyun Yang
Digestive Diseases and Sciences.2020; 65(4): 1189. CrossRef
Passion fruit (Passiflora edulis) leaf aqueous extract ameliorates intestinal epithelial barrier dysfunction and reverts inflammatory parameters in Caco-2 cells monolayer
Mônica Cristina Lopes do Carmo, Isabela Mateus Martins, Ana Elisa Ramos Magalhães, Mário Roberto Maróstica Júnior, Juliana Alves Macedo
Food Research International.2020; 133: 109162. CrossRef
Efficacy and safety of abrilumab, an α4β7 integrin inhibitor, in Japanese patients with moderate-to-severe ulcerative colitis: a phase II study
Toshifumi Hibi, Satoshi Motoya, Toshifumi Ashida, Souken Sai, Yukinori Sameshima, Shiro Nakamura, Atsuo Maemoto, Masahiro Nii, Barbara A Sullivan, Robert A. Gasser Jr, Yasuo Suzuki
Intestinal Research.2019; 17(3): 375. CrossRef

7,711 View
137 Download
8 Web of Science
9 Crossref

Original Articles

Diagnostic and prognostic value of preoperative ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography for colorectal cancer: comparison with conventional computed tomography: Joo Young Lee, Soon Man Yoon, Jeong Tae Kim, Ki Bae Kim, Mi Jin Kim, Jae Geun Park, Taek-Gu Lee, Sang-Jeon Lee, Sung Soo Koong, Joung-Ho Han, Hee Bok Chae, Seon Mee Park, Sei Jin Youn; Intest Res 2017;15(2):208-214. Published online April 27, 2017; DOI: https://doi.org/10.5217/ir.2017.15.2.208

Abstract PDF PubReader ePub

Background/Aims

¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) has been used for preoperative staging of colorectal cancer (CRC). However, the diagnostic accuracy of FDG-PET/CT for detection of lymph node or distant metastasis and its prognostic role have not been well established. We therefore evaluated the diagnostic and prognostic value of FDG-PET/CT in comparison with conventional CT for CRC.

Methods

We investigated 220 patients who underwent preoperative FDG-PET/CT and CT, followed by curative surgery for CRC. The sensitivity, specificity, accuracy, positive predictive value, and negative predictive value of FDG-PET/CT and CT for detection of lymph node metastasis and distant metastasis were evaluated. In addition, we assessed the findings of FDG-PET/CT and CT according to outcomes, including cancer recurrence and cancer-related death, for evaluation of prognostic value.

Results

For detection of lymph node metastasis, FDG-PET/CT had a sensitivity of 44%, a specificity of 84%, and an accuracy of 67%, compared with 59%, 65%, and 62%, respectively, for CT (P=0.029, P=0.000, and P=0.022). For distant metastasis, FDG-PET/CT had a sensitivity of 79%, a specificity of 94%, and an accuracy of 93%, compared with 79%, 87%, and 86%, respectively, for CT (P=1.000, P=0.004, and P=0.037). In addition, positive findings of lymph node metastasis and distant metastasis on FDG-PET/CT were associated significantly with cancer recurrence or cancer-related death (P=0.009, P=0.001, respectively).

Conclusions

Preoperative FDG-PET/CT had a higher specificity and accuracy compared to CT for detection of lymph node metastasis and distant metastasis of CRC. In addition, FDG-PET/CT could be a valuable prognostic tool for CRC.

Citations

Citations to this article as recorded by

Nuclear medicine based multimodal molecular imaging facilitates precision medicine for gastrointestinal tumors
Jing Zhao, Fei Wang, Rong-Fu Wang
World Chinese Journal of Digestology.2024; 32(10): 727. CrossRef
Tomographie par émission de positons en cancérologie digestive
C. Aveline, F. Montravers
EMC - Radiologie et imagerie médicale - Abdominale - Digestive.2024; 42(1): 1. CrossRef
Retrospective audit: Utility of PET scan in routine preoperative rectal cancer staging
Michelle Zhiyun Chen, Xinyi Zhang, Milton Mui, Joseph C. H. Kong, Alexander G. Heriot, Jodie Ellis‐Clark
ANZ Journal of Surgery.2023; 93(3): 617. CrossRef
Impact of routine preoperative 18FDG PET/CT on the surgical management of primary colorectal cancer
Mónica Mogollón‐González, Raquel Conde‐Muiño, Antonio Rodríguez‐Fernández, Mar Navarro‐Pelayo, Mireia Domínguez‐Bastante, Pablo Palma
Journal of Surgical Oncology.2023; 128(2): 295. CrossRef
Investigating ultra-low-dose total-body [18F]-FDG PET/CT in colorectal cancer: initial experience
Hui Tan, Danjie Cai, Xiuli Sui, Chi Qi, Wujian Mao, Yiqiu Zhang, Guobing Liu, Haojun Yu, Shuguang Chen, Pengcheng Hu, Jianying Gu, Hongcheng Shi
European Journal of Nuclear Medicine and Molecular Imaging.2022; 49(3): 1002. CrossRef
Tailoring the clinical management of colorectal cancer by 18F-FDG PET/CT
Yang Shi, Meiqi Wang, Jiyu Zhang, Zheng Xiang, Can Li, Jingjing Zhang, Xing Ma
Frontiers in Oncology.2022;[Epub] CrossRef
Clinical TNM staging for esophageal, gastric, and colorectal cancers in the era of neoadjuvant therapy: A systematic review of the literature
Hideaki Shimada, Takeo Fukagawa, Yoshio Haga, Shin‐ichi Okazumi, Koji Oba
Annals of Gastroenterological Surgery.2021; 5(4): 404. CrossRef
The significant value of predicting prognosis in patients with colorectal cancer using 18F-FDG PET metabolic parameters of primary tumors and hematological parameters
Junyan Xu, Yi Li, Silong Hu, Linjun Lu, Zhiqi Gao, Huiyu Yuan
Annals of Nuclear Medicine.2019; 33(1): 32. CrossRef
Optimal Interval for 18F-FDG-PET After Chemoradiotherapy for Rectal Cancer
Kazushige Kawai, Hiroaki Nozawa, Keisuke Hata, Toshiaki Tanaka, Takeshi Nishikawa, Koji Oba, Toshiaki Watanabe
Clinical Colorectal Cancer.2018; 17(2): e163. CrossRef
Preoperative PET/CT 18F-FDG Standardized Uptake by Lymph Nodes as a Significant Prognostic Factor in Patients with Colorectal Cancer
Ruohua Chen, Yining Wang, Xiang Zhou, Gang Huang, Jianjun Liu
Contrast Media & Molecular Imaging.2018; 2018: 1. CrossRef

6,611 View
63 Download
10 Web of Science
10 Crossref

A retrospective analysis of 20-year data of the surgical management of ulcerative colitis patients in Taiwan: a study of Taiwan Society of Inflammatory Bowel Disease: Chun-Chi Lin, Shu-Chen Wei, Been-Ren Lin, Wen-Sy Tsai, Jinn-Shiun Chen, Tzu-Chi Hsu, Wei-Chen Lin, Tien-Yu Huang, Te-Hsin Chao, Hung-Hsin Lin, Jau-Min Wong, Jen-Kou Lin; Intest Res 2016;14(3):248-257. Published online June 27, 2016; DOI: https://doi.org/10.5217/ir.2016.14.3.248

Abstract PDF PubReader ePub

Background/Aims

With the recent progress in medical treatment, surgery still plays a necessary and important role in treating ulcerative colitis (UC) patients. In this study, we analyzed the surgical results and outcomes of UC in Taiwan in the recent 20 years, via a multi-center study through the collaboration of Taiwan Society of IBD.

Methods

A retrospective analysis of surgery data of UC patients from January 1, 1995, through December 31, 2014, in 6 Taiwan major medical centers was conducted. The patients' demographic data, indications for surgery, and outcome details were recorded and analyzed.

Results

The data of 87 UC patients who received surgical treatment were recorded. The median post-operative follow-up duration was 51.1 months and ranged from 0.4 to 300 months. The mean age at UC diagnosis was 45.3±16.0 years and that at operation was 48.5±15.2 years. The 3 leading indications for surgical intervention were uncontrolled bleeding (16.1%), perforation (13.8%), and intractability (12.6%). In total, 27.6% of surgeries were performed in an emergency setting. Total or subtotal colectomy with rectal preservation (41.4%) was the most common operation. There were 6 mortalities, all due to sepsis. Emergency operation and low pre-operative albumin level were significantly associated with poor survival (P=0.013 and 0.034, respectively).

Conclusions

In the past 20 years, there was no significant change in the indications for surgery in UC patients. Emergency surgeries and low pre-operative albumin level were associated with poor survival. Therefore, an optimal timing of elective surgery for people with poorly controlled UC is paramount.

Citations

Citations to this article as recorded by

Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease updated in 2023
Hsu-Heng Yen, Jia-Feng Wu, Horng-Yuan Wang, Ting-An Chang, Chung-Hsin Chang, Chen-Wang Chang, Te-Hsin Chao, Jen-Wei Chou, Yenn-Hwei Chou, Chiao-Hsiung Chuang, Wen-Hung Hsu, Tzu-Chi Hsu, Tien-Yu Huang, Tsung-I Hung, Puo-Hsien Le, Chun-Che Lin, Chun-Chi Lin
Intestinal Research.2024; 22(3): 213. CrossRef
Minimally Invasive Surgical Approach to Toxic Colitis
Zhobin Moghadamyeghaneh, Murwarid Rahimi, Katherine Kopatsis, Anthony Paul Kopatsis, Anthony Kopatsis
The American Surgeon.2022; 88(7): 1411. CrossRef
Effectiveness and safety of acupuncture therapy for inflammatory bowel disease: a protocol of systematic review and meta-analysis
Yuan-Fang Zhou, Ning Sun, Shi-Rui Cheng, Xiao-Dong Deng, Xiang-Yin Ye, Zheng-Jie Li, Jun Zhou, Gui-Xing Xu, Yu-Zhu Qu, Liu-Yang Huang, Rui-Rui Sun, Fan-Rong Liang
BMJ Open.2021; 11(8): e045090. CrossRef
Recent Advance in the Management of Dysplasia in the Ulcerative Colitis
Dong-Hoon Yang
Journal of Digestive Cancer Reports.2021; 9(2): 50. CrossRef
Trends and risk factors of mortality analysis in patients with inflammatory bowel disease: a Taiwanese nationwide population-based study
Wei-Chen Lin, Meng-Tzu Weng, Chien-Chih Tung, Yuan-Ting Chang, Yew-Loong Leong, Yu-Ting Wang, Horng-Yuan Wang, Jau-Min Wong, Shu-Chen Wei
Journal of Translational Medicine.2019;[Epub] CrossRef
Variant Two-Stage Ileal Pouch-Anal Anastomosis: An Innovative and Effective Alternative to Standard Resection in Ulcerative Colitis
Jennifer Samples, Krista Evans, Nicole Chaumont, Paula Strassle, Timothy Sadiq, Mark Koruda
Journal of the American College of Surgeons.2017; 224(4): 557. CrossRef

5,401 View
50 Download
6 Web of Science
6 Crossref

Old Age at Diagnosis Is Associated With Favorable Outcomes in Korean Patients With Inflammatory Bowel Disease: Jae Hyuk Choi, Eun Soo Kim, Kwang Bum Cho, Kyung Sik Park, Yoo Jin Lee, Sang Min Lee, Yu Jin Kang, Byung Ik Jang, Kyeong Ok Kim; Intest Res 2015;13(1):60-67. Published online January 29, 2015; DOI: https://doi.org/10.5217/ir.2015.13.1.60

Abstract PDF PubReader

Background/Aims

Despite the rising incidence and prevalence of inflammatory bowel disease (IBD) in Asian populations, data regarding clinical characteristics of patients in Asia based on age at diagnosis are relatively sparse. The aim of this study was to compare clinical characteristics based on the age at diagnosis according to the Montreal Classification in Korean IBD patients.

Methods

We recruited consecutive patients with IBD at two tertiary hospitals and retrospectively reviewed their medical information. Patients were divided into three groups according to their age at diagnosis: youth (<17 years), young adult (17-40 years), and middle-old (>40 years). The main clinical characteristics for comparison were the achievement of a remission state at the last follow-up visit, cumulative rate of surgery, and cumulative use of immunomodulators and tumor necrosis factor-α (TNFα) blockers during the follow-up period.

Results

In total, 346 IBD patients were included (Crohn's disease [CD] 146 and ulcerative colitis 200; 36 youth, 202 young adult, and 113 middle-old). The middle-old group with CD was characterized by a predominance of uncomplicated behavior (P=0.013) and a lower frequency of perianal disease (P=0.009). The middle-old group was associated more with a less aggressive disease course than the younger group, as shown by more frequent remission (P=0.004), being less likely to undergo surgery (P<0.001), and lower cumulative use of immunomodulators and TNFα blockers (P<0.001).

Conclusions

Age at diagnosis according to the Montreal Classification is an important prognostic factor for Korean IBD patients.

Citations

Citations to this article as recorded by

Impact of age at diagnosis on long‐term prognosis in patients with intestinal Behçet's disease
Ji Young Chang, Soo Jung Park, Jae Jun Park, Tae Il Kim, Jae Hee Cheon, Jihye Park
Journal of Gastroenterology and Hepatology.2024; 39(3): 519. CrossRef
Peripheral blood neutrophil-to-lymphocyte ratio in inflammatory bowel disease and disease activity: A meta-analysis
Wei Fu, Hu Fu, Weixia Ye, Yinsuo Han, Xianqiang Liu, Sirui Zhu, Hongmin Li, Rong Tang, Qin Wang
International Immunopharmacology.2021; 101: 108235. CrossRef
Earlier Anti-Tumor Necrosis Factor Therapy of Crohn’s Disease Correlates with Slower Progression of Bowel Damage
Hinaben Panchal, Mathilde Wagner, Manjil Chatterji, Bachir Taouli, Russell McBride, Jeromy R. Patterson, Ryan Ungaro, Marla Dubinsky, Judy Cho, David B. Sachar
Digestive Diseases and Sciences.2019; 64(11): 3274. CrossRef
Characteristics and management of patients with inflammatory bowel disease between a secondary and tertiary hospitals: a propensity score analysis
Ki Hwan Song, Eun Soo Kim, Yoo Jin Lee, Byung Ik Jang, Kyeong Ok Kim, Sang Gyu Kwak, Hyun Seok Lee
Intestinal Research.2018; 16(2): 216. CrossRef
Risk Factors for Vitamin D, Zinc, and Selenium Deficiencies in Korean Patients with Inflammatory Bowel Disease
Yoo Min Han, Hyuk Yoon, Soo Lim, Mi-Kyung Sung, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee, Joo Sung Kim
Gut and Liver.2017; 11(3): 363. CrossRef
Sampling Strategies for Three-Dimensional Spatial Community Structures in IBD Microbiota Research
Shaocun Zhang, Xiaocang Cao, He Huang
Frontiers in Cellular and Infection Microbiology.2017;[Epub] CrossRef
Influence of age at diagnosis on the clinical characteristics of Crohn's disease in Korea: Results from the CONNECT study
Sung Wook Hwang, Jee Hyun Kim, Jong Pil Im, Byong Duk Ye, Hoon Sup Koo, Kyu Chan Huh, Jae Hee Cheon, You Sun Kim, Young Ho Kim, Dong Soo Han, Won Ho Kim, Joo Sung Kim
Journal of Gastroenterology and Hepatology.2017; 32(10): 1716. CrossRef
Impact of inflammatory bowel disease on daily life: an online survey by the Korean Association for the Study of Intestinal Diseases
Young Sun Kim, Sung-Ae Jung, Kang-Moon Lee, Soo Jung Park, Tae Oh Kim, Chang Hwan Choi, Hyun Gun Kim, Won Moon, Chang Mo Moon, Hye Kyoung Song, Soo-Young Na, Suk-Kyun Yang
Intestinal Research.2017; 15(3): 338. CrossRef
Clinical Efficacy of Beclomethasone Dipropionate in Korean Patients with Ulcerative Colitis
Yoon Jee Lee, Jae Hee Cheon, Jae Hyun Kim, SunHo Yoo, Hyun Jung Lee, Soo Jung Park, Sung Pil Hong, Tae Il Kim, Won Ho Kim
Yonsei Medical Journal.2017; 58(1): 144. CrossRef
Prediction of low bone mineral density in patients with inflammatory bowel diseases
Solvey Schüle, Jean‐Benoît Rossel, Diana Frey, Luc Biedermann, Michael Scharl, Jonas Zeitz, Natália Freitas‐Queiroz, Valérie Pittet, Stephan R Vavricka, Gerhard Rogler, Benjamin Misselwitz
United European Gastroenterology Journal.2016; 4(5): 669. CrossRef
Effect of mucosal healing (Mayo 0) on clinical relapse in patients with ulcerative colitis in clinical remission
Jae Hyun Kim, Jae Hee Cheon, Yehyun Park, Hyun Jung Lee, Soo Jung Park, Tae Il Kim, Won Ho Kim
Scandinavian Journal of Gastroenterology.2016; 51(9): 1069. CrossRef
Patients with perianal Crohn's disease have poor disease outcomes after primary bowel resection
Yoo Min Han, Ji Won Kim, Seong‐Joon Koh, Byeong Gwan Kim, Kook Lae Lee, Jong Pil Im, Joo Sung Kim, Hyun Chae Jung
Journal of Gastroenterology and Hepatology.2016; 31(8): 1436. CrossRef
Clinical features of Crohn's disease in Korean patients residing in Busan and Gyeongnam
Eun Ji Lee, Tae Oh Kim, Geun Am Song, Jong hun Lee, Hyung Wook Kim, Sam Ryong Jee, Seun Ja Park, Hyun Jin Kim, Jong Ha Park
Intestinal Research.2016; 14(1): 30. CrossRef
The Positive Influences of Increasing Age at Diagnosis of Inflammatory Bowel Disease on Disease Prognostication in Asian Perspective
Raja Affendi Raja Ali
Intestinal Research.2015; 13(1): 4. CrossRef
Continuous duodenal levodopa infusion in a patient with Crohn's disease and small bowel surgery — Case report
Svetlana Tomic, Danijela Skelac, Dario Mick, Ivan Segec, Bojan Resan, Silva Butkovic Soldo
Journal of the Neurological Sciences.2015; 358(1-2): 525. CrossRef

6,232 View
54 Download
15 Web of Science
15 Crossref

Long-Term Clinical Outcomes of Korean Patient With Crohn's Disease Following Early Use of Infliximab: Nam Hee Kim, Yoon Suk Jung, Chang Mo Moon, Shin Yeong Lee, Eun Ran Kim, Young Ho Kim, Chang Kyun Lee, Suck Ho Lee, Jae Hak Kim, Kyu Chan Huh, Soon Man Yoon, Hyun Joo Song, Sun-Jin Boo, Hyun Joo Jang, You Sun Kim, Kang-Moon Lee, Jeong Eun Shin, Dong Il Park; Intest Res 2014;12(4):281-286. Published online October 27, 2014; DOI: https://doi.org/10.5217/ir.2014.12.4.281

Abstract PDF PubReader ePub

Background/Aims

Several recent studies have reported that the early use of infliximab (IFX) improves the prognosis of Crohn's disease (CD). However, no data are available from Asian populations, as the forementioned studies have all been conducted in Western countries. The aim of the current study was to evaluate the impact of early use of IFX on the prognosis of Korean patients with CD.

Methods

Patients with a diagnosis of CD established between July 1987 and January 2012 were investigated in 12 university hospitals in Korea. Because insurance coverage for IFX treatment began in August 2005, patients were assigned to either of 2 groups based on diagnosis date. The first group included patients diagnosed from July 1987 to December 2005, and the second from January 2006 to January 2012. We compared the cumulative probabilities of operation and reoperation between the two groups using the Kaplan-Meier method and a log-rank test.

Results

Of the 721 patients investigated, 443 (61.4%) comprized the second group. Although the cumulative probabilities of immunosuppressant (P<0.001) and IFX use (P<0.001) after diagnosis were significantly higher in the second group, there were no significant differences in cumulative probabilities of operation (P=0.905) or reoperation (P=0.418) between two groups.

Conclusions

The early use of IFX did not reduce CD-related surgery requirements in Korean patients with CD. These study results suggest that the early use of IFX may have little impact on the clinical outcome of CD in Korean patients in the setting of a conventional step-up algorithm.

Citations

Citations to this article as recorded by

The Potential of Molecular Remission: Tissue Neutrophil Elastase Is Better Than Histological Activity for Predicting Long-Term Relapse in Patients With Ulcerative Colitis in Endoscopic Remission
Yu Kyung Jun, Hyeon Jeong Oh, Ji Ae Lee, Yonghoon Choi, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee, Hyuk Yoon
Inflammatory Bowel Diseases.2025; 31(2): 514. CrossRef
Differences in the risk of clinical failure between thiopurine and methotrexate in bio-naïve patients with Crohn’s disease: a Korean nationwide population-based study
Yu Kyung Jun, Eunjeong Ji, Hye Ran Yang, Yonghoon Choi, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee, Hyuk Yoon
Therapeutic Advances in Gastroenterology.2024;[Epub] CrossRef
Efficacy of COVID-19 vaccines in inflammatory bowel disease patients receiving anti-TNF therapy: A systematic review and meta-analysis
Dan Dou, Fangyi Zhang, Xin Deng, Yun Ma, Shuqing Wang, Xingyu Ji, Xihan Zhu, Dianpeng Wang, Shengsheng Zhang, Luqing Zhao
Heliyon.2023; 9(9): e19609. CrossRef
Pharmacodynamic mechanisms behind a refractory state in inflammatory bowel disease
Rasmus Goll, Øystein K. Moe, Kay-Martin Johnsen, Renate Meyer, Joachim Friestad, Mona D. Gundersen, Hege Kileng, Knut Johnsen, Jon R. Florholmen
BMC Gastroenterology.2022;[Epub] CrossRef
Editorial: does anti‐TNF “treatment persistence” always equate to “effective treatment”? Only objective disease assessments can answer the question
Ashish Srinivasan, Daniel R. van Langenberg
Alimentary Pharmacology & Therapeutics.2021; 54(5): 718. CrossRef
Blocking tumor necrosis factor paved the way for targeted therapeutics in inflammatory diseases
Cong-Qiu Chu
Chinese Medical Journal.2021; 134(21): 2525. CrossRef
A State-of-the-Art Review of New and Emerging Therapies for the Treatment of IBD
Kenechukwu O Chudy-Onwugaje, Kaci E Christian, Francis A Farraye, Raymond K Cross
Inflammatory Bowel Diseases.2019; 25(5): 820. CrossRef
Efficacy of Anti-TNF Therapy for the Treatment of Patients with Moderate-to-Severe Inflammatory Bowel Disease; a First Iranian Report
Samaneh Mohagheghi Darehranj, Sudabeh Alatab, Homayoon Vahedi, Anahita Sadeghi, Alireza Sima, Masoud Malekzadeh, Amir Anoshiravani, Hafez Fakheri, Nasser Ebrahimi Daryani, Abdolhamid Mousavi, Fariborz Mansour-Ghanaei, Mohammad Javad Zahedi, Reza Malekzade
Middle East Journal of Digestive Diseases.2019; 12(1): 12. CrossRef
Novel treatments for inflammatory bowel disease
Hyo Sun Lee, Soo-Kyung Park, Dong Il Park
The Korean Journal of Internal Medicine.2018; 33(1): 20. CrossRef
Association of Perianal Fistulas with Clinical Features and Prognosis of Crohn's Disease in Korea: Results from the CONNECT Study
Jaeyoung Chun, Jong Pil Im, Ji Won Kim, Kook Lae Lee, Chang Hwan Choi, Hyunsoo Kim, Jae Hee Cheon, Byong Duk Ye, Young-Ho Kim, You Sun Kim, Yoon Tae Jeen, Dong Soo Han, Won Ho Kim, Joo Sung Kim
Gut and Liver.2018; 12(5): 544. CrossRef
Physicians Should Provide Shared Decision-Making for Anti-TNF Therapy to Inflammatory Bowel Disease Patients
Jae Myung Cha, Dong Il Park, Sang Hyoung Park, Jeong Eun Shin, Wan Soo Kim, Suk-Kyun Yang
Journal of Korean Medical Science.2017; 32(1): 85. CrossRef
Fecal microbiota transplantation for refractory Crohn's disease
Seon Ho Bak, Hyun Ho Choi, Jinhee Lee, Mi Hee Kim, Youn Hee Lee, Jin Su Kim, Young-Seok Cho
Intestinal Research.2017; 15(2): 244. CrossRef
Long-Term Outcomes of Infliximab Treatment in 582 Korean Patients with Crohn’s Disease: A Hospital-Based Cohort Study
Sang Hyoung Park, Sung Wook Hwang, Min Seob Kwak, Wan Soo Kim, Jeong-Mi Lee, Ho-Su Lee, Dong-Hoon Yang, Kyung-Jo Kim, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Yong Sik Yoon, Chang Sik Yu, Jin-Ho Kim, Suk-Kyun Yang
Digestive Diseases and Sciences.2016; 61(7): 2060. CrossRef
Factors Contributing to the Preference of Korean Patients with Crohn's Disease When Selecting an Anti-Tumor Necrosis Factor Agent (CHOICE Study)
Eun Soo Kim, Kyeong Ok Kim, Byung Ik Jang, Chang Kyun Lee, Hyo Jong Kim, Kang-Moon Lee, You Sun Kim, Chang Soo Eun, Sung-Ae Jung, Suk-Kyun Yang, Jun Lee, Tae-Oh Kim, Yunho Jung, Geom Seog Seo, Soon Man Yoon
Gut and Liver.2016;[Epub] CrossRef
The Efficiency of Intravenous Iron Therapy in Korean Inflammatory Bowel Disease Patients
Kyeong Ok Kim
Gut and Liver.2016; 10(4): 487. CrossRef
Clinical features of Crohn's disease in Korean patients residing in Busan and Gyeongnam
Eun Ji Lee, Tae Oh Kim, Geun Am Song, Jong hun Lee, Hyung Wook Kim, Sam Ryong Jee, Seun Ja Park, Hyun Jin Kim, Jong Ha Park
Intestinal Research.2016; 14(1): 30. CrossRef
Advanced age impacts surgical characteristics and postoperative course in patients with Crohn's disease
Stanislaus Argeny, Anton Stift, Martina Mittlböck, Amy C. Lord, Svenja Maschke, Mathias Schneeweiß, Stefan Riss
International Journal of Surgery.2016; 33: 182. CrossRef
The clinical usefulness of a web-based messaging system between patients with Crohn disease and their physicians
Da Eun Jeong, Kyeong Ok Kim, Byung Ik Jang, Eun Young Kim, Jin Tae Jung, Seong Woo Jeon, Hyun Seok Lee, Eun Soo Kim, Kyung Sik Park, Kwang Bum Cho
Medicine.2016; 95(26): e4028. CrossRef
The clinical characteristics of patients with free perforation in Korean Crohn’s disease: results from the CONNECT study
Young Seok Doh, You Sun Kim, Song I Bae, Jong Pil Im, Jae Hee Cheon, Byong Duk Ye, Ji Won Kim, Young Sook Park, Ji Hyun Lee, Young-Ho Kim, Joo Sung Kim, Dong Soo Han, Won Ho Kim
BMC Gastroenterology.2015;[Epub] CrossRef
Management of Anemia in Patients with Inflammatory Bowel Disease
Kyeong Ok Kim
The Korean Journal of Gastroenterology.2015; 65(3): 145. CrossRef
Could Early Anti-Tumor Necrosis Factor Therapy Change the Prognosis of Crohn's Disease?
Byong Duk Ye
Intestinal Research.2014; 12(4): 263. CrossRef

5,802 View
60 Download
20 Web of Science
21 Crossref

Prediction of Tumor Recurrence in Patients with Non-Gastric Gastrointestinal Stromal Tumors Following Resection according to the Modified National Institutes of Health Criteria: Seung Hyeon Jang, Ji Eun Kwon, Jee Hyun Kim, June Young Lee, Sang Gyun Kim, Joo Sung Kim, Hyun Chae Jung, Jong Pil Im; Intest Res 2014;12(3):229-235. Published online July 25, 2014; DOI: https://doi.org/10.5217/ir.2014.12.3.229

Abstract PDF PubReader ePub

Background/Aims

Few studies have investigated the prognosis of non-gastric gastrointestinal stromal tumors (GISTs) under the modified National Institutes of Health (NIH) consensus criteria in Korea. This study aims to clarify the clinical usefulness of the modified NIH criteria for risk stratification.

Methods

From January 2000 through October 2012, 88 patients who underwent curative resection for primary GISTs were included in this study. The enrolled patients were stratified to predict recurrence by the original NIH criteria and modified NIH criteria.

Results

In all, 88 patients had non-gastric GISTs, including 82 and 6 patients with GISTs of the small intestine and colorectum, respectively. The mean age was 57.3±13.0 years, and the median follow-up duration was 3.40 years (range, 0.02-12.76 years). All patients who were placed in the intermediate-risk category according to the original NIH criteria were reclassified into the high-risk category according to the modified NIH criteria. Therefore, the proportion of cases in the intermediate-risk category declined to 0.0% from 25.0% (22/88), and the proportion of cases in the high-risk category increased to 43.2% (38/88) from 18.2% (16/88) under the modified NIH criteria. Among the 22 reclassified patients, 6 (27.3%) suffered a recurrence during the observational period, and the recurrence rate of high-risk category patients was 36.8% (14/38).

Conclusions

Patients in the high-risk category according to the modified NIH criteria had a high GIST recurrence rate. Therefore, the modified NIH criteria are clinically useful in selecting patients who need imatinib adjuvant chemotherapy after curative surgical resection.

Citations

Citations to this article as recorded by

Survival outcome and impact of delayed imatinib therapy in gastric gastrointestinal stromal tumors
R. Jansuwan, S. Samphao, Wongsakorn Chaochankit
Frontiers in Surgery.2025;[Epub] CrossRef
Population-based long-term prognosis analysis of subcutaneous gastrointestinal stromal tumors
Luojie Liu, Xinyu Shao
Surgical Endoscopy.2024; 38(12): 7298. CrossRef
Radiologic Review of Small Bowel Malignancies and Their Mimicking Lesions
Jong Soo Lee, So Hyun Park, Seung Joon Choi
Journal of the Korean Society of Radiology.2023; 84(1): 110. CrossRef
Assessment of a Real-world Learning Curve for the Endoscopic Resection of Gastric Gastrointestinal Stromal Tumors
Ying Sun, Luojie Liu, Dongtao Shi, Chao Ma, Xiaodan Xu
Journal of International Medical Research.2023;[Epub] CrossRef
Gastrointestinal Stromal Tumors of the Stomach and Esophagus
Lauren Theiss, Carlo M. Contreras
Surgical Clinics of North America.2019; 99(3): 543. CrossRef
Comparison of Different Risk Classification Systems in 558 Patients with Gastrointestinal Stromal Tumors after R0-Resection
Michael Schmieder, Doris Henne-Bruns, Benjamin Mayer, Uwe Knippschild, Claudia Rolke, Matthias Schwab, Klaus Kramer
Frontiers in Pharmacology.2016;[Epub] CrossRef
A High Risk Group in the Modified National Institutes of Health Consensus Criteria for the Gastrointestinal Stromal Tumor: A Clear Indication of the Adjuvant Imatinib
Dong Kyung Chang
Intestinal Research.2014; 12(3): 176. CrossRef

37,807 View
56 Download
8 Web of Science
7 Crossref

First
Prev
Page of 1
Next
Last

Search